(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/048944 Al 15 March 2018 (15.03.2018) W !P O PCT

(51) International Patent Classification: A61K38/1 7 (2006.01) C07K 14/575 (2006.01) A61P 3/00 (2006.01) A61K 38/22 (2006.01) (21) International Application Number: PCT/US2017/050334 (22) International Filing Date: 06 September 2017 (06.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/383,957 06 September 2016 (06.09.2016) US (71) Applicant: LA JOLLA PHARMCEUTICAL COMPA¬ NY [US/US]; 10182 Telesis Court, 6th Floor, San Diego, CA 92121 (US). (72) Inventors: TD3MARSH, George; 45 Tintern Lane, Porto- la Valley, CA 94028 (US). CHAWLA, Lakhmir; 10586 Abalone Landing Ter, San Diego, CA 92 130 (US). = (74) Agent: HALSTEAD, David, P. et al; Foley Hoag LLP, = 155 Seaport Boulevard, Boston, MA 02210-2600 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = KR, KW,KZ, LA, LC, LK, LR, LS, LU, LY,MA, MD, ME, = MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, ≡ TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. — (84) Designated States (unless otherwise indicated, for every ~ kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, ≡ EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, ≡ TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = KM, ML, MR, NE, SN, TD, TG).

— Declarations under Rule 4.17: — of inventorship (Rule 4.1 7(iv)) < Published: — with international search report (Art. 21(3))

00 © 00 (54) Title: METHODS OF TREATING IRON OVERLOAD © (57) Abstract: Provided herein are compositions and methods related to the use of hepcidin and/or hepcidin analogues for the treatment and/or prevention of iron overload in a subject (e.g., a human subject) and/or for reducing serum iron levels in a subject without inducing serum iron rebound. METHODS OF TREATING IRON OVERLOAD

RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application serial number 62/383,957, filed September 6, 2 6, which is herein incorporated by reference in its entirety.

BACKGROUND Iron is an essential element required for growth and survival of almost every organism. In mammals, the iron balance is primarily regulated at the level of duodenal absorption of dietary iron. Following absorption, ferric iron is loaded into apo-transferrin in the circulation and transported to the tissues, including erythroid precursors, where it is taken up by transferrin receptor-mediated endocytosis. Reticuloendothelial macrophages play a major role in the recycling of iron from the degradation of hemoglobin of senescent erythrocytes, while hepatocytes contain most of the iron stores of the organism in ferritin polymers. In the case of iron deficiency, the pathophysiological consequences of gene defects identified are well understood because they usually result in loss of function of proteins directly involved in the pathway of iron absorption. The proteins include the iron transporters DMT1 (also called Nramp2 or DCTl), ferroportin (also called IREG1 or MTPl), and copper oxidases coupled to ferroportin, namely ceruloplasmin and haephastin. Iron overload (also referred to as hemochromatosis) is the exact opposite of iron deficiency, and refers to the over-accumulation of iron in the body. Chronic iron overload can lead to a number of detrimental conditions, including cirrhosis of the liver, diabetes, cardiomyopathy and arthritis. The genetic disorder hereditary hemochromatosis (HHC) is a relatively common autosomal recessive genetic disease that results in the hyperabsorption of dietary iron leading to an iron overload in plasma and organs. The excess iron is stored in the body's tissues and organs, particularly the skin, heart, liver, pancreas, and joints. Because humans cannot increase the excretion of iron, excess iron can overload and eventually damage tissues and organs. Once diagnosed, hemochromatosis is often treated by phlebotomy to rid the body of excess iron and to maintain normal iron stores. Phlebotomy, an invasive and inefficient therapy, remains the sole recommended treatment for hereditary hemochromatosis . Beta thalassemias (β thalassemias) are a group of inherited blood disorders caused by reduced or absent synthesis of the beta chains of hemoglobin that result in outcomes ranging from severe anemia to clinically asymptomatic individuals. Current treatments include repeated blood transfusions, which can result in transfusional iron overload. In many patients with β thalassemia, multiple blood transfusions, ineffective erythropoiesis, and increased gastrointestinal iron absorption lead to iron overload in the body. Iron overload impairs the immune system, placing patients at greater risk of infection and illness. To counter this iron overload, patients often undergo chelation therapy. Many common chelators used for treating iron overload are associated with toxicity and renal impairment, hepatic impairment and gastrointestinal hemorrhage . Thus, there is a need for new treatments for iron overload and related disorders that are safer and better tolerated.

SUMMARY Provided herein are compositions and methods related to the use of hepcidin and/or hepcidin analogues for the treatment and/or prevention of iron overload in a subject (e.g., a human subject) and/or for reducing serum iron levels in a subject. The compositions and methods provided herein are related, in part, to the discover}' of serum iron level rebound following hepcidin therapy under some conditions. Following hepcidin administration at higher doses, some patients experience a serum iron level rebound, in which serum iron levels initially drop in response to hepcidin administration, but then paradoxically rise (or rebound) above baseline iron level (i.e., the level of serum iron prior to hepcidin administration). The compositions and methods described herein follow from the observation that this undesirable rebound in serum iron level can be avoided or mitigated by initially administering low doses of hepcidin (e.g., 1-20 mg, preferably 1- 0 mg, or even more preferably 1-5 mg), and/or increasing the frequency of administration of lower doses to heighten the effects of hepcidin therapy (rather than administer doses above 40 mg, or even above 30 mg or even above 20 mg). The need for increasing the frequency or dose of hepcidin administration can be identified from measurements of serum or tissue iron levels in the patient (for example, serum iron levels, ferritin levels, transferrin saturation, hemoglobin, or hematocrit) and comparing these measurements to predetermined target levels. In certain embodiments, the methods provided herein include administering to the subject hepcidin or a hepcidin analogue at an amount sufficient to reduce the serum iron concentration in the subject without inducing a serum iron level rebound following treatment. In some embodiments, the amount of hepcidin or hepcidin analogue is between about 0.1mg and about 40 mg. In some embodiments, the amount of hepcidin or hepcidin analogue is between 1 mg and about 3 mg (e.g.. between about 5 mg and about 3 mg, between about 10 mg and about 30 mg, between about 20 mg and about 30 mg, between about 1 mg and about 20 mg, between about 5 mg and about 20 mg, between about mg and about 20 mg, between about 1mg and about 10 mg, between about 5 mg and about mg). In some embodiments, the amount of hepcidin or hepcidin analogue is about 0.1 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, mg, mg, 12 mg, 3 rng, 14 mg, 15 mg, 16 rng, 17 mg, 18 mg, 19 rng, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 3 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg or 40 mg. Provided herein are methods of treating or preventing iron overload in a subject and/or reducing serum iron levels in a subject by administering to the subject a hepcidin or hepcidin analogue at an amount sufficient to reduce the serum iron concentration of the subject, wherein administering the hepcidin or hepcidin analogue comprises administering the hepcidin or hepcidin analogue at an initial dose below the threshold to induce serum iron rebound. In some embodiments, the methods further comprise administering to the subject an additional dose or doses of the hepcidin or hepcidin analogue, e.g., on a periodic basis (e.g., biweekly, weekly, semiweekly, daily), which doses may be the same as the initial dose or higher or lower depending on whether the patient has experienced the desired clinical response. The additional dose or doses may be below the threshold to induce serum iron rebound (e.g., 40 mg or less, preferably 30 mg or less, or even 20 mg or less). The additional dose or doses may be the same as the threshold dose to induce serum iron rebound. e additional dose or doses may be higher than the threshold dose to induce serum iron rebound. In some embodiments, the initial dose of the hepcidin or hepcidin analogue is sufficient to measurably reduce serum iron concentration, and can be from about 0.1 ng to about 40 mg, preferably from about 1 mg to about 30 mg (e.g.. from about 5 mg to about 30 mg, from about 10 mg to about 30 mg, from about 20 mg to about 30 mg, from about 1 mg to about 20 mg, from about 5 mg to about 20 mg, from about 10 mg to about 20 mg, from about 1 mg to about 0 mg, from about 5 mg to about 0 mg). In some embodiments, the initial dose of the hepcidin or hepcidin analogue is about 0 .1mg, 0.5 mg, 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, mg, 12 mg, 13 mg, 14 mg, 15 mg, 6 mg, 17 mg, 1 nig, mg, 20 mg, nig, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 rng, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg or 40 mg. In some embodiments, the additional dose or doses of the hepcidin or hepcidin analogue are sufficient to measurably reduce serum iron concentration, and can be from about 0.1 mg to about 40 mg, such as from about 1mg to about 30 mg (e.g., from about 5 mg to about 30 mg, from about mg to about 30 mg, from about 20 g to about 30 mg, from about 1nig to about 20 mg, from about 5 nig to about 20 nig, from about 0 mg to about 20 mg, from about 1 mg to about 0 mg, from about 5 mg to about 0 mg). In some embodiments, the additional dose or doses of the hepcidin or hepcidin analogue are about 0.1 mg, 0.5 mg, 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg,

12 mg, 13 nig, 4 mg, 15 mg, 16 nig, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 rng, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg or 40 mg. The additional doses described herein may be the same, higher, or lower than the initial dose, and/or the frequency of administration may be increased or reduced, e.g., to achieve a desired effect on the patient's serum iron level or other therapeutic parameter without inducing a rebound effect. Methods described herein may include increasing the dose of the hepcidin or hepcidin analogue from one dose to a subsequent dose. Methods described herein may include decreasing the dose of the hepcidin or hepcidin analogue from one dose to a subsequent dose. Methods described herein may include increasing the frequency of administering the hepcidin or hepcidin analogue (e.g., from biweekly to weekly, or weekly to semi-weekly). Methods described herein may include decreasing the frequency of administering the hepcidin or hepcidin analogue (e.g., from semi-weekly to weekly, or from weekly to biweekly). In some embodiments, the method further comprises measuring the patient's serum iron level. In some embodiments, the method comprises adj usting or titrating the dose of administration in response to a subject's serum iron measurement. In some embodiments, the amount of hepcidin or hepcidin analogue is such that the subject's transferrin saturation level is reduced to between 15% and 50% (e.g., between 20% and 50%, between 20% and 40%). The hepcidin or hepcidin analogue may be administered

(e.g., through subcutaneous injection) in a in a single dose or in multiple doses over a period of time (e.g., once a day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, once every 7 days, once every- 8 days, once every- nine days, once every 10 days, once every 1 days, once every 12 days, once every 13 days, or once every 4 days). n some embodiments, the hepcidin or hepcidin analogue is administered twice a week, once a week, once every 10 days or once every two weeks. In some embodiments, the amount of hepcidin or hepcidin analogue is administered as necessary

(e.g.. when the subject experiences above-normal serum iron concentrations or above normal transferrin saturation levels (e.g., above 50%, above 60%, above 70%, above 80%, above 90% or above 95% transferrin saturation)). In some embodiments, the amount of hepcidin or hepcidin analogue is administered each time the hepcidin or hepcidin analogue is administered. In some embodiments, the hepcidin or hepcidin analogue is a mini-hepcidin. In some embodiments, the hepcidin or hepcidin analogue is adm inistered in an amount sufficient to increase the level of hepcidin in the subject, reduce the serum ferritin concentration in the subject, reduce the total body iron level in the subject, reduce the serum iron concentration in the subject, and/or reduce the transferrin saturation in the subject. In some embodiments, the hepcidin administered is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% monomer. In some embodiments, the hepcidin administered is no more than 10%, 9%, 8%, 7%, 6%, 5%, 4% 3%, 2% or 1% aggregated. In some embodiments, provided herein are formulations compri sing an amount of hepcidin or a hepcidin analogue sufficient to reduce the serum iron concentration in the subject without inducing a serum iron level rebound following treatment. In some embodiments, the amount of hepcidin or hepcidin analogue is between about 0. mg and about 40 mg. In some embodiments, the amount of hepcidin or hepcidin analogue is between

1 mg and about 30 ng (e.g., between about 5 mg and about 30 mg, between about 10 mg and about 30 mg, between about 20 mg and about 30 mg, between about 1 mg and about 20 mg, between about 5 mg and about 20 mg, between about mg and about 20 mg, between about

1 mg and about 10 mg, between about 5 mg and about 1 mg). In some embodiments, the amount of hepcidin or hepcidin analogue is about 0.1 mg, 0.5 mg, 1 rng, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 0 mg, mg, 12 mg, 3 mg, 14 mg, 5 mg, 6 mg, 7 mg, mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 2 8 mg, 29 mg, 30 rng, 3 mg, 32 mg, 33 rng, 34 mg, 35 mg, 36 rng, 37 mg, 38 mg, 39 mg or 40 rng. In some embodiments, the hepcidin in the formulation is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% monomer. In some embodiments, the hepcidin administered is no more than 10%, 9%, 8%, 7%, 6%, 5%, 4% 3%, 2% or 1% aggregated. In some embodiments, the hepcidin or hepcidin analogue is a mini-hepcidin. In some embodiments, the formulation comprises hepcidin or hepcidin analogue in an amount sufficient to increase the level of hepcidm in the subject, reduce the seram ferritin concentration in the subject, reduce the total body iron level in the subject, reduce the seram iron concentration in the subject, and/or reduce the transferrin saturation in the subject. In some embodiments, the subject treated according to the methods provided herein has or is at risk of iron overload. In some embodiments, the subject has a transferrin saturation level of at least 50%, 60%, 70%, 80%, 90% or 95%. In some embodiments, the subject treated according to the metliods provided herein has elevated seram iron levels. In some embodiments, the subject has β-thalassemia, hemochromatosis, sickle cell disease, or anemia, such as refractory anemia, hemolytic anemia, hemoglobinopathy, sideroblastic anemia, an anemia associated with myelodysplasia syndrome (MDS), or a congenital anemia. In some embodiments, the subject has liver disease (such as liver cancer), cardiomyopathy, or diabetes. The subject may have a bacterial {e.g., Escherichia coli, Neisseria cinerea, Neisseria gonorrhoeae. Staphylococcus epidermidis, Staphylococcus aureus, or Streptococcus agalactiae), viral (e.g., hepatitis B, hepatitis C, or dengue virus), fungal {e.g., Candida albicans), or protist (e.g., Trypanosoma cruzi, Plasmodium {e.g., P. falciparum, P. vivax P. ovale, or P. malariae), Trypanosoma brucei (such as T. brucei gambiense or T. brucei rhodesiense) or Leishmania) infection. In some embodiments, the subject has received a blood transfusion (e.g., within the previous week, within the previous 48 hours, etc.). In some embodiments, the subject has transfusional iron overload.

BRIEF DESCRIPTION OF DRAWINGS Figure I shows the serum iron percent change for subjects administered 1 mg, 5 mg, 10 mg and 20 mg doses of hepcidin. Figure 2 shows the percent change in serum iron through day 7 of subjects administered a 1 mg dose, a 5 mg dose, a mg dose, a 20 mg dose and a 30 mg dose of hepcidin.

DETAILED DESCRIPTION General As described herein, administration of a sufficient dose of hepcidin to a subject results in reduced serum iron level in the subject and the treatment of iron overload. However, surprisingly, administration of hepcidin to the subject above a certain threshold can produce a "rebound effect", such that, following an initial drop, the serum iron levels in the subject rise to above-baseline levels following treatment (e.g., within 30 hours of treatment, within 48 hours of treatment, within 72 hours of treatment, within 96 hours of treatment, or within about 3 to 96 hours of treatment). Provided herein are methods and compositions related to the administration of hepcidin or hepcidin analogues to a subject at an amount that sufficient to lower the subject's serum iron level but below a level that would induce seram iron level rebound following treatment. In some embodiments, the amount of hepcidin or hepcidin analogue is such that the subject's transferrin saturation level is reduced to between 5% and 50% (e.g., between 20% and 50%, between 20% and 40%). In certain embodiments, the methods provided herein include administering to the subject hepcidin or a hepcidin analogue at an amount sufficient to reduce the serum iron concentration in the subject without inducing a serum iron level rebound following treatment. In some embodiments, provided herein are formulations comprising an amount of hepcidin or a hepcidin analogue sufficient to reduce the serum iron concentration in the subject without inducing a seram iron level rebound following treatment. In some embodiments, the amount of hepcidin or hepcidin analogue is between about 0. mg and 50 mg, between about 1 mg and about 30 mg, between about 5 mg and about 30 mg, between about 10 mg and about 30 mg, between about 20 mg and about 30 mg, between about 1 mg and about 20 mg, between about 5 mg and about 20 mg, between about mg and about 20 mg, between about 1 mg and about 10 mg, or between about 5 mg and about 10 mg. In some embodiments, the amount of hepcidin or hepcidin analogue is about 0. mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about

0.9 mg, about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about mg, about mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 1 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 3 rng, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg or about 40 mg.

Definitions For convenience, certain terms employed in the specification, examples, and appended claims are collected here. The articles "a" and " " are used herein to refer to one or to more than one (i.e., to a least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element. As used herein, the term "about" and 'approximately" shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Typically, exemplar degrees of error are within 20%, preferably within 10%, and more preferably within 5% of a given value or range of values. Alternatively, and particularly in biological systems, the terms "about" and "approximately" may mean values that are within an order of magnitude, preferably within 5-fold and more preferably within 2- fold of a given value. Numerical quantities given herein are approximate unless stated otherwise, meaning that the term "about" or "approximately" can be inferred when not expressly stated. As used herein, the term "administering" means providing a pharmaceutical agent or composition to a subject, and includes, but is not limited to, administering by a medical professional and self-administering. Such an agent, for example, may be hepcidin or a hepcidin analogue. As used herein, the phrase "pharmaceutically acceptable" refers to those agents, compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as phamiaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyi cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; ( 11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; ( ) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; ( ) polyesters, polycarbonates and/or polyanhydrides; and (22) other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, a therapeutic that "prevents" a condition {e.g., iron overload) refers to a compound that, when administered to a statistical sample prior to the onset of the disorder or condition, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample. In certain embodiments, agents of the invention may be used alone or conjointly administered with another type of therapeutic agent. As used herein, the phrase "conjoint administration" refers to any form of administration of two or more different therapeutic agents such that the second agent is administered while the previously administered therapeutic agent is still effective in the body {e.g., the two agents are simultaneously effective in the subject, which may include synergistic effects of the two agents). For example, the different therapeutic agents can be administered either in the same formulation or in separate formulations, either concomitantly or sequentially. In certain embodiments, the different therapeutic agents can be administered within about one hour, about 2 hours, about 24 hours, about 36 hours, about 48 hours, about 72 hours, or about a week of one another. T ms, a subject who receives such treatment can benefit from a combined effect of different therapeutic agents. As used herein, serum iron rebound" or "iron rebound ' refers to an increase in serum iron concentration to above-normal or above-baseline levels in a subject following an initial hepcidin-induced decrease in serum iron concentration (e.g., within 30 hours of administering hepcidin or a h pcid n analog, within 48 hours of administering hepcidin or a hepcidin analog, within 72 hours of hepcidin or a hepcidin analog, or within 96 hours of hepcidin or a hepcidin analog). As disclosed herein, serum iron rebound occurs after a subject has been administered an amount of hepcidin or a hepcidin analogue above a threshold level. In some embodiments, serum iron rebound is reflected by increased serum iron concentration in a subject following hepcidin or hepcidin analogue administration (e.g., within 48 hours of administration, within 72 hours of administration, or within 96 hours of administration) relative to the subject's serum iron concentration prior to hepcidin or hepcidin analogue administration. For example, in certain embodiments, serum iron rebound is indicated when the serum iron concentration in a subject following hepcidin or hepcidin analogue administration is at least 100%, 105%, 110%, 115%, 120%, 125%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or 200% of the subject's seram iron concentration before hepcidin administration s used herein, the term b means a human or non-human animal selected for treatment or therapy. The phrases "therapeutically-effective amount" and 'effective amount" as used herein means the amount of an agent which is effective for producing the desired therapeutic effect in at least a sub-population of cells in a subject at a reasonable benefit/risk ratio applicable to any medical treatment. Treating" a disease in a subject or "treating" a subject having a disease refers to subjecting the subject to a pharmaceutical treatment, e.g. , the administration of a drag, such that at least one symptom of the disease is decreased or prevented from worsening.

Hepcidin and Hepcidin Analogues Hepcidin is a 25-amino acid peptide with the amino acid sequence set forth in SEQ ID O:l .

SEQ ID DTHFPICIFCCGCCHRS KCGMCCKT

The hepcidin peptide is a cleavage product of a larger protein, and the cell membrane protein furin can convert an extracellular hepcidin precursor protein into hepcidin peptide. The term "hepcidin or hepcidin analogue" as used herein may refer to a peptide comprising the sequence set forth in SEQ ID NO: 1, including peptides that are longer than 25 amino acids, such as peptides consisting of 26 to 00 amino acids, as well as any variant of the hepcidin peptide that retains hepcidin function. For example, conservative amino acid substitutions, additions, and deletions may be made to SEQ D NO:l without significantly affecting the function of hepcidin. Thus, the term "hepcidin or hepcidin analogue" may refer to a peptide comprising an amino acid sequence having at least 6Q%>, 64 % , 68%, 72%, 76% 80%, 84%, 88%, 92%, 96%, or 100% sequence homology or identity with the amino acid sequence set forth in SEQ ID NO:l that retains hepcidin activity. Sequence homology or identity may be determined using any suitable sequence alignment program, such as Protein Blast (blastp) or Clustal (e.g., ClustalV, ClustalW, ClustalX, or Clustal Omega), e.g., using default parameters, such as default weights for gap openings and gap extensions. The term "hepcidin or hepcidin analogue" may refer to a peptide comprising an amino acid sequence that is identical to the sequence set forth in SEQ ID NO: 1 except that 1, 2 , 3, 4, 5, 6, 7, 8, 9, or 10 ammo acids of SEQ ID NO: 1 are substituted with different amino acids, e.g., that preferably retains the disulfide-bonding of naturally occurring hepcidin. In some embodiments, hepcidin comprises a cysteine at each of the positions in which a cysteine occurs in SEQ ID O:l . In some embodiments, the hepcidin is at least 80% monomer. For example, in some embodiments, the hepcidm is at least %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% monomer. In some embodiments, the hepcidin is no more than 0%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% aggregates

(e.g., aggregates larger than dimers). N-terminal and C-terminal residues may be deleted from the hepcidin peptide without significantly affecting its activity. Thus, in some embodiments, "hepcidin or hepcidin analogue" may include a peptide comprising the sequence set forth in SEQ ID NO:2, SEQ ID NO: 3, or SEQ ID NO:4, or a peptide comprising an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85% 90%, 95% or 100% sequence homology or identity with the ammo acid sequence set forth in SEQ ID NO: , SEQ ID NO:3, SEQ ID NO:4, or SEQ ID O:5.

SEQ ID :/. PICIFCCGCCHRSKCGMCCKT

SEQ ID NO:3 PICIFCCGCCHRSKCGMCC

SEQ ID NO:4 ICIFCCGCCHRSKCGMCCKT

SEQ ID NO:5 CIFCCGCCHRSKCGMCC The term "hepcidin or hepcidin analogue" may refer to a peptide comprising an amino acid sequence that is identical to the sequence set forth in SEQ ID NO:2, SEQ ID

NQ:3, SEQ ID NO:4, or SEQ ID : except that 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NG:4, or SEQ ID NO:5 are substituted with different amino acids. In some embodiments, hepcidin or the hepcidin analogue comprises a cysteine at each of the positions in which a cysteine occurs in SEQ ID NO:2, SEQ D NO:3, SEQ ID NO:4, or SEQ ID NO:5 . In some embodiments, the term "hepcidin or hepcidin analogue" refers to a peptide comprising an amino acid sequence that is identical to the sequence set forth in SEQ ID NO:6, SEQ ID NO: 7. SEQ ID NO: 8, SEQ ID NQ:9, or SEQ ID NO: 10. In SEQ ID NO:6, SEQ ID N 7. SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO: 10, the ammo acids labeled "X" may be any amino acid, including naturally occurring and non-naturally occurring amino acids. In some embodiments, each of the amino acids labeled "X" is a naturally occurring amino acid.

SEQ ID NO:6 XXHXPXCXXCCGCCHRSKCGMCCXX

SEQ ID NO: 7 PXCXXCCGCCHRSKCGMCCKX

SEQ ID NO: PXCXXCCGCCHRSKCG MCC

SEQ ID NO: XCXXCCGCCHRXXCGXCCKX

SEQ ID NO: 10 CXXCCGCCHRXXCGXCC

In some embodiments, "hepcidin or hepcidin analogue" is a molecule that specifically binds to ferroportin and/or iron (e.g., an iron cation). Hepcidin or a hepcidin analogue may comprise 1, 2, 3, or 4 disulfide bonds. In some embodiments, hepcidin comprises four disulfide bonds. n some embodiments, each of the four disulfide bonds is an intramolecular disulfide bond. In some embodiments, each of the eight cysteines of SEQ ID

NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 participates in one of four intramolecular disulfide bonds with another one of the eight cysteines. In some embodiments, ' hepcidin or hepcidin analogue" may include a peptide comprising the sequence set forth in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO: 10, or a peptide comprising an amino ac d sequence having at least 60%, 65%, 70%, 75%, 80%, 85% 90%, 95% or 100% sequence homology or identity with the amino acid sequence set forth in SEQ ID NO:6, SEQ D NO. . SEQ ID NO: 8, SEQ D NO: 9 or SEQ ID NO: 10. In some embodiments, hepcidin or the hepcidin analogue has about 10% to 00% of the activity of a 25 ammo acid long peptide comprising the amino acid sequence set forth in SEQ ID NO:l, i.e., wherein the 25 amino acid long peptide comprises the four intramolecular disulfide bonds found in native human hepcidin. For example, hepcidm may have about 50% to about 200% of the activity of a 25 amino acid long peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 (i.e., wherein the 25 amino acid long peptide comprises the four intramolecular disulfide bonds found in native human hepcidin), such as about 75% to about 150% of the activity, about 80% to about 20% of the activity, about 90% to about 10% of the activity, or about 95% to about 105% of the activity. The term "activity" may refer to the ability of hepcidin or the hepcidin analogue to specifically bind to ferroportin, . ., thereby inhibiting the transport of intracellular iron into the extracellular space, inhibiting the absorption of dietary iron, and/or reducing serum iron concentration. Activity may refer to the ability of hepcidin or the hepcidin analogue to inhibit the transport of intracellular iron into the extracellular space. Activity may refer to the ability of hepcidin to inhibit the absorption of dietary iron. Activity may refer to the ability of hepcidin or hepcidin analogue to reduce excess iron in vivo. Activity may refer to the ability of hepcidin or hepcidin analogue to reduce serum iron concentration in vivo. Because of the different potencies of various hepcidin analogues, unless otherwise specified herein, a specific dose of hepcidin or a hepcidin analogue should be understood as that dose of hepcidin or a dose of a hepcidin analogue that achieves the same therapeutic effect (e.g., the same reduction in serum iron levels) as the specified dose of hepcidin. In some embodiments, hepcidin or the hepcidin analogue may refer to a mini- hepcidm, a modified hepcidin, or a hepcidin mimetic peptide. The structure of the bioactive 25-amino acid form of hepcidin is a hairpin with 8 cysteines that form 4 disulfide bonds as described by Jordan et al. (2009) J Biol Chem 284:24155-67, which is hereby incorporated by reference in its entirety. The N-termmal region has been shown to be required for iron- regulatory function, and deletion of 5 N-terminal amino acid residues results in a loss of iron-regulatory function. This finding has resulted in the design of drug-like hepcidin mimetic peptides (Preza et al., Clin Invest. 201 ; 121(12):4880-4888), which is hereby incorporated by reference in its entirety. Hepcidin mimetic peptides or modified hepcidins are peptides that exert the function of reducing serum iron concentration as bioactive hepcidin. For the purposes of this application, the terms mini-hepcidin, a modified hepcidin, or a hepcidin mimetic peptide may be used interchangeably Mini-hepcidins, a modified hepcidin, and hepcidin mimetic peptides are disclosed in US. Patent No. 9,315,545, 9,328,140, and 8,435,941, and in U.S. Publication number US2015284429, each of which is hereby incorporated by reference, in particular for their disclosure of compounds that share one or more activities with hepcidin.

A mini-hepcidin may have the structure of Formula I :

(1) wherein R i is, —S—Zi; — 2, Si !. —C(=0)— or —-S—C(=0)— Z3, i is substituted or unsubstituted Ci-Cis alky] or Ci-Cis alkenyl, wherein the Ci-Cis alkyl or Ci-Cis alkenyl is branched or unbranched or Zi is an electron withdrawing or donating group;

Z,2 is substituted or unsubstituted Ci-Cis alkyl or Ci-Cis alkenyl, wherein the Ci-Cis alkyl or Ci-C s alkenyl s branched or unbranched or Z 2is an electron withdrawing or donating group:

Z 3 is substituted or unsubstituted Ci-Cis alkyl or Ci-Cis alkenyl, wherein the Ci-Cis alkyl or

Ci-Cis alkenyl is branched or unbranched or Z 3 is an electron withdrawing or donating group. A mini-he cidin may have the simcture of any one of Formulas II-IV:

(II)

mini-hepcidin may have the structure of Formula V:

(V) wherein:

: is, . —S— Zi; / . . — SH, ( ·(=()) ·.. or — S— C(=0)— Z 3,

R 2and R 3 are each, independently, optionally substituted C4-C7 alkyl,

D-Arg, D-Ile, Leu, D-Leu, Thr, D-Thr, Lys, D-Lys, Val, D-Val, D~Nco,co~dimethy3-arginine, L-No),ai-dimethyl-arginine, D-homoarginine, L-homoarginine, D-norarginine, L- norarginine, citruiline, a modified Arg wherein the guanidinium group is modified or substituted, norleucine, norvaSine, beta homo-lie, 1-aniinocyclohexane-l-carboxylic acid, N-Me-Arg, N-Me-I3e;

R 1S Ida, Asp, Acetyl-Asp, (methylamino)pentanedioic acid, Acetyl-Gly-Ida, or Acetyl-Gly- Asp or a derivative thereof to remove its negative charge above pH 4;

R 5 is C -. as l o heteroasyl; B is absent or forms a 5-7 membered ring; and q s 0-6, wherein when R aryl or heteroaryl q is 1and B is absent; Z i is substituted or unsubstituted Ci-Cis alkyl, wherein the Ci-Cis alkyl is branched or unbranched; Z 2is substituted or unsubstituted C1-C18 alkyl, wherein the Ci-Cis alkyl is branched or unbranched;

Z 3 is substituted or unsubstituted C -C s alkyl, wherein the Ci-Cis alkyl is branched or unbranched; and R are each, independently, H, halo, optionally substituted Ci-C alkyl, or haloalkyl, provided that when R is H, the compound does not have the structure of Formula XVI. -hepcidin may have the structure of any one of Formulas VI-VIII: (VIII) wherein the variables are defined as for Formula V. -hepcidin may have the structure of Formula IX:

wherein Ri is H, — S—Zi, —¾ — SH, — S— C(=0)— Z3, or — C(==0>—Z ,

R?. and R 3 are each, independently, optionally substituted C - a ky ,

D~Arg, D- e, Leu, D-Leu, Thr, D-Thr, Lys, D-Lys, Val, D-Val, D~N ,c -dm etl yl-arginine, L-N -dimethyl-arginine, D-homoarginine, L-homoarginine, D-norarginine, L- norarginine, citrulline, a modified Arg wherein the guanidinium group is modified or substituted, norleucme, norvaline, beta homo-lie, 1-aminocyclohexane-l-carboxylic acid, N-Me-Arg, N-Me~Ile; R is Ida, Asp, Acetyl-Asp, (methylamino)pentanedioic acid, Acetyl-Gly-Ida, or Acetyl-Gly- Asp or a derivative thereof to remove its negative charge above pH 4; B is absent or forms a 5-7 membered ring; Z i is substituted or unsubstituted C1-C18 alkyl, wherein the C1-C18 a ky is branched or unbranched; Ί is substituted or unsubstituted Ci-Cis alky], wherein the Ci-Cis alkyl is branched or unbranched; and

Z 3 is substituted or unsubstituted Ci-Cis alkyl, wherein the C1-C18 alkyl is branched or unbranched; provided that when Ri is H, the compound does not have the stmcture of Formula XVI. A mini-hepcidin may have the structure of Formula X :

(X) wherein the variables are defined as for Formula IX -hepcidin may have the structure of Formula XI:

(XI)

/herein the carbonyl forms a bond with the 6-membered ring at CA, C , or C and with variables as defined for Formula IX. (XII) wherein the carbonvl forms a bond with the 5-membered ring at Cdor C and with the variables as defined for Formula IX A mini-hepcidin may have the structure of Formula XIII:

(XIII) wherein the bond from the carbonyl forms a bond with the 7-membered ring at Cf, Cg, C , or Ciand with the variables as defined for Formula IX.

-hepcidin may have the structure of Formula XIV: mini-hepcidin may have the structure of Formu la XV:

(XV) A mini-hepcidin may have the structure of Formula P -P -P -P--Ps-P -P -P -P -P or

P10-P9-P8-P7-P6-P5-P4-P3-P2-P1, wherein P to Pio are as defined in table 1; X 3 is Ahx- Ida(NH-PAL)-NH2, Ida is Iminodiacetic acid; Dpa is 3,3-diphenyl-L-alanine; bhPro is beta- homoproiine; pc is L-nipecotic acid; isoNpc is isonipecotic acid; and bAla is beta-alanine.

Table 1 -hepcidin may have the structure of Formula XV :

(XVI) A mini-hepcidin may have the structure of formula A1-A2-A3-A4-A5-A6-A7-A8- A9-A , A 0-A9-A8-A7-A6-A5-A4-A3-A2-A , wherein: A is L-Asp, L-Glu, pyroglutamate, L-Gln, L-Asn, D-Asp, D-Glu, D-pyroglutamate, D-Gln, D-Asn, 3-aminopentanedioic acid, 2,2'-azanediyidiacetic acid, (methylamino)pentanedioic acid, L-Ala, D-Ala, L-Cys, D-Cys, L-Phe, D-Phe, L-Asp, D-Asp 3,3-diphenyl-L-alanine, 3,3-diphenyl-D-alanine; and if A i is L-Asp or D- Asp, then A2 is L-Cys or D-Cys; if A l is L-Phe or D-Phe, then the N-terminus is optionally attached to a PEG molecule linked to chenodeoxvcholate, ursodeoxvcholate, or palmitoyl; or if A l is 3,3-diphenyl-L-alanine or 3,3-diphenyl-

D-alanine, then the N-terminus is attached to palmitoyl;

A 2 is L-Thr, L-Ser, L-Vai, L-Ala, D-Thr, D-Ser, D-Val, L-tert-leucine, isonipecotic acid, L -

a-cyclohexylglycine, bhThr, (2S)-3-hydroxy-2-(methylamino)butanoic acid, D-Ala,

L-Cys, D-Cys, L-Pro, D-Pro, or G y;

A 3 is L-His, D-His, 3,3-diphenyl-L-alanine, 3,3-diphenyl-D-alanine, or 2-aminoindane;

A 4 is L-Phe, D-Phe, (S)-2-amino-4-phenylbutanoic acid, 3,3-diphenyi-L-alanine, L-

biphenylalanme, (l-naphthyl)-L-alanine, (S)-3-Amino-4,4-diphenylbutanoic acid, 4 -

(aminomethyl)cyclohexane carboxylic acid, (S)-2-amino-3-

(perfluorophenyl)propanoic acid, (S)-2-amino-4-phenylbutanoic acid, (S)-2-amino-2-

(2,3-dihydro-lH-inden-2-yl)acetic acid, o r cyclohexylalanine;

A 5 is L-Pro, D-Pro, octahydroindole-2 -carboxylic acid, L-P-homoproline, (2S,4S)-4-

phenylpyrrolidine-2 -carboxylic acid, (2S,5R)-5-phenylpyrrolidine-2-carboxylic acid,

or (R)-2-methylindoline;

A 6 is L-Ile, D-Ile, L-phenylglycine, L-a-cyclohexylglycine, 4-(aminomethyl)cyclohexane

carboxylic acid, (3R)-3-amino-4-methylhexanoic acid, 1-aminocyclohexane-l-

carboxylic acid, or (3R)-4-methyl-3-(meth}damino)hexanoic acid;

Al is L-Cys, D-Cys, S-t-Butylthio-L-cysteine, L-homocysteine, L-penicillamine, or D- penicillaniine;

A 8 is L-Ile, D-Ile, L-a-cyclohexylglycine, 3,3-diphenyl-L-alanine, (3R)-3-amino-4-

methylhexanoic acid, 1-aminocyclohexane-l -carboxylic acid, or (3R)-4-methyl-3-

(methylaniino)hexanoic acid;

A 9 is L-Phe, L-Leu, L-Ile, L-Tyr, D-Phe, D-Leu, D-Ile, (S)-2-amino-3-

(perfluorophenyl)propanoic acid, N-methyl-phenylalainine, benzylamide, (S)-2-

amino-4-phenylbutanoic acid, 3,3-diphenyl-L-alanine, L-biphenylalaniiie, (1-

naphthyl)-L-alanine, (S)-3-amino-4,4-diphenylbutanoic acid, cyclohexylalanine, L-

Asp, D-Asp, or cysteamide, wherein L-Phe or D-Phe are optionally linked a t the N -

terminus to RA, wherein RA is -CONH-CH2-CH2-S-, or D-Pro linked to Pro-Lys or

Pro-Arg, or L-p-homoproline linked to L-Pro linked to Pro-Lys or Pro-Arg, or D-Pro

linked to L-P-homoproline-Lys or L-P-homoproline-Arg; L-Asp or D-Asp are

optionally linked at the n-terminus to RB, wherein R B is -(PEG 11)-

GYIPEAPRDGQAYVRKDGEWVLLSTFL, or -(PEG l)-(Gly-Pro-HydroxyPro )io,

(S)-2-amino-4-phenylbutanoic acid is linked to RC, wherein R C is D-Pro linked to ProLys or ProArg, or D-Pro linked to L-P-homoproline-Lys or ,-β-homoproline- L- Arg; A ) is L-Cys, L-Ser, L-Ala, D-Cys, D-Ser, or D-Ala; the carboxy-terminal amino acid is in amide or carboxy- form; at least one sulfhydryl amino acid is present as one of the amino acids in the sequence; and Al, A2, A l to A2, A 10, A 9 to A 10, or a combination thereof are optionally absent. A mini-hepcidin of formula A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 or A10-A9-A8- A7-A6-A5-A4-A3-A2-A1 may be a cyclic peptide or a linear peptide. For example, A l may be L-Asp; A2, may be L-Th; A 3 may be L-His; A 4 may be L- Phe; A 5 may be L-Pro; A 6 may be L-Ile; A 7 may be L-Cys, D-Cys, S-t-butylthio-L-cysteine, L-homocysteine, L-penicillaniine, or D-penicillamine; A 8 may be L-Ile; A9 may be L-Phe; A 10 may be absent; and the C-terminus may be amidated. Alternatively, A 3 may be L-His; A4 may be L-Phe; A 5 may be L-Pro; A 6 may be L-Ile; A 7 may be L-Cys, D-Cys, S-t- butylthio-L-cysteine, L-homocysteine, L-penicillamine, or D-penicillamine; A 8 may be L- le; Al, A2, A9, and A10 may be absent, and the C-terminus may be amidated. Alternatively, A3 may be L-His; A4 may be L-Phe; A 5 may be L-Pro; A6 may be L-Ile; A7 may be L-Cys, D-Cys, S-t-butylthio-L-cysteine, L-homocysteine, L-penicillamine, or D- penicillamine: Al, A2, A8, A9, and A10 may be absent; and the C-terminus may be amidated.

A mini-hepcidin, may comprise the amino acid sequence HFPICI (SEQ ID NO:l 1), HFPICIF (SEQ ID NO: 12), DTHFPICIDTHFPICIF (SEQ ID NO: 13), DTHFPIAIFC (SEQ ID NO: 4), DTOAPICIF (SEQ ID NO: 5), DTHFPICIF (SEQ ID NO: 16), or CDTHFPICIF

(SEQ ID NO: 17). The mini-hepcidin may comprise the sequence set forth in SEQ ID NO: 15, for example, wherein the cysteine forms a disulfide bond with S-tertbutyl. A mini-hepcidin may comprise the amino acid sequence D-T-H-F-P-I-(L- homocysteine)-I-F; D-T-H-F-P-I-(L-penicillamine)-I-F; D-T-H-F-P-I-(D-penicillamine)-I-F; D-(L-tert-leucine)-H-(L-phenylglycine)-(octahydroindole-2-carboxylic acid)-(L-a- cyclohexylglycine)-C-(L-a-cyclohexylglycine)-F: or D-(L-tert-leucine)-H-P- (octahydromdole-2-carboxylic acid)-(L-a-cyclohexyiglycine)-C~(L-a-cyciohexylglycine)-F. A mini-hepcidin may comprise the amino acid sequence FICIPFHTD (SEQ ID NO: 18), FICIPFH (SEQ ID NO: 19), R2-F1CIPFHTD (SEQ ID NO:20), R3-FICIPFHTD (SEQ ID NG:21), FICIPFHTD-R6 (SEQ ID NO:22), R4-FICIPFHTD (SEQ ID NO: 23). or

R5-FICIPFHTD (SEQ ID NO:24), wherein each ammo acid is a D amino acid; R 1 is - CONH2-CH2-CH2-S; R2 is chenodeoxycholate-(PEG )-; R3 is ursodeoxychoiate-(PEG )- ; R4 is palms toy! -(PEG 11)-; R5 is 2(palmitoyl)-diaminopropionic acid-(PEG )-; and R 6 is (PEG 1)-GYIPEAPRDGQAYVRKDGEWVLLSTTL, wherein each amino acid of R 6 is an L amino acid. A mini-hepcidin may comprise the am o acid sequence D-T-H-((S)-2-amino-4- phenylbutanoic acid)-P-l-C-I-F; D-T-H-(3,3-diphenyl-L-alanine)-P-I-C-I-F; D-T-H-(L-

iph n !a!aninc)-P-i-C-i - : > ~ - - S amino-4,4-diphenylbutanoic acid)-P-I-C-I-F; D-T-H-F-P-I-C-I-((S)-2-amino-4- phenylbutanoic acid); D-T-H-F-P-I-C-I-(3,3-diphenyl-L-alanine); D-T-H-F-P-I-C-I-(L- biphenylalamne); D-T-H-F-P-I-C4-((l-naphthyl)-L-alanine); D-T-H-F-P-I-C-I-((S)-3- amino-4,4-diphenylbutanoic acid); D-T-H-(3,3-diphenyl-L-alanine)-P-I-C-I-(3,3-diphenyl-L- alanine); D-(3,3-diphenyl-L-alanine)-P-I-C-I-F; D-(3,3-diphenyl-L-alanine)-P-I-C-I-(3,3- diphenyl-L-alanine); D-T-H-(3,3-diphenyl-L-alanine)-P-R-C-R-(3,3-diphenyl-L-alanine); D-

T-H-(3 ,3-diphenyl-L-alanine)-(octahydroindole-2-carboxylic acid)-I-C-l-F; D-T-H-(3 ,3- diphenyl-L-a3anine)-(octahydroindole-2-carboxylic acid)-I-C-I-(3,3-diphenyl-L-alanine); or D-T-H-(3,3-diphenyl-L-alanine)-P-C-C-C-(3,3-diphenyl-L-alanine). A mini-hepcidin may comprise the ammo acid sequence D-T-H-F-P-I-C-1-F-R8; D-

T-H-F-P-I-C-I-F-R9; D-T-H-F-P-I-C-I-F-R 10; D-T-H-F-P-I-C-I-F-Rl ; D-T-H-F-P-I-C-I-F- R12; D-T-H-F-P-I-C-I-F-R 13; D-T-H-F-P-I-C-I-((S)-2-amino-4-phenylbutanoic acid)-R8; D-T-H-F-P-I-C-I-((S)-2-amino-4-phenylbutanoic acid)-R9; D-T-H-F-P-I-C-I-((S)-2-amino- 4-phenylbutanoic acid)-R12; or D-T-H-F-P-l-C-I-((S)-2-amino-4-phenylbutanoic acid)-R13, wherein R 8 is D-Pro-L-Pro-L-Lys; R9 is D-Pro-L-Pro-L-Arg; R is (L-P-homoproline)-L- Pro-L-Lys; R is (L-P-homoproline)-L-Pro-L-Arg; R12 is D-Pro-(L -P-homoproline)-L-Lys; and R13 is D-Pro-(L-p-homoproline)-L-Arg. A mini-hepcidin may comprise the amino acid sequence D-T-H-(3,3-diphenyl-L- alanine)-P-(D)R-C-(D)R-(3,3-diphenyl-L-alanine). A mini-hepcidin may comprise he amino acid sequence C-(isonipecoiic acid)-(3,3- diphenyl-D-alanine)-(4-(aminomethyl)cyclohexane carboxylic acid)-R-(4- (aminomethyl)cyclohexane carboxylic acid)-(isonipecotic acid)-(3,3-diphenyl-L-alanine)- cysteamide. A mini-hepcidin may comprise he amino acid sequence C-P-(3,3-diphenyl-D- alanine)-(4-(aminomethyl)cyclohexane carboxylic acid)-R-(4-(aminomethyl)cyclohexane carboxylic acid)-(isonipecotic acid)-(3,3-diphenyl-L~alanine)-cysteamide. A mini-hepcidin may comprise the amino acid sequence C-(D)P-(3,3-diphenyl-D-alanine)-(4- (aminomethyl)cyclohexane carboxylic acid)-R-(4-(aniinomethyl)cyclohexane carboxylic acid)-(isonipecotic acid)-(3,3-diphenyl-L-alanine)-cysteamide. A mini-hepcidin may comprise the amino acid sequence C-G-(3,3-diphenyl-D-alanine)-(4- (aminomethyl)cyclohexane carboxylic acid)-R-(4-(aminomethyl)cyclohexane carboxylic acid)-(isonipecotic acid)-(3,3-diphenyl-L-alanine)-cysteamide. In some embodiments, a mini-hepcidin has about 10% to 1000% of the activity of a

25 amino acid long peptide comprising the amino acid sequence set forth in SEQ ID NO: 1.

For example, a mini-hepcidin may have about 50% to about 2Q0%> of the activity of a 25 amino acid long peptide comprising the amino acid sequence set forth in SEQ ID NO: 1, such as about 75% to about 50% of the activity, about 80% to about 120% of the activity, about 90% to about 1 0% of the activity, or about 95% to about 105% of the activity. The term "activity " may refer to the ability of a mini-hepcidin to specifically bind to ferroportin, e.g. , thereby inhibiting the transport of intracellular iron into the extracellular space, inhibiting the absorption of dietary iron, and/or reducing serum iron concentration. Activity may refer to the ability of a mini-hepcidin to inhibit the transport of intracellular iron into the extracellular space. Activity may refer to the ability of a mini-hepcidin to inhibit the absorption of dietary iron. Activity may refer to the ability of a mini-hepcidin to reduce serum iron concentration in vivo.

Dosing In certain aspects, provided herein are methods for treating or preventing iron overload in subject related to the administration to the subject hepcidin or a hepcidin analogue at an amount sufficient to reduce the serum iron concentration of the subject without inducing a serum iron level rebound. In certain aspects, provided herein are formulations for treating or preventing iron overload in subject comprising hepcidin or a hepcidin analogue in an amount sufficient to reduce the serum iron concentration of the subject without inducing a serum iron level rebound. In some embodiments, the amount of hepcidin or hepcidin analogue is such that the subject's transferrin saturation level is reduced to between 15% and 50% (e.g., between 20% and 50%, between 20% and 40%). In some embodiments, iron rebound is elevated serum iron levels post hepcidin or hepcidin analogue administration. Provided herein are methods of treating or preventing iron overload in a subject and/or reducing serum iron levels in a subject by administering to the subject a hepcidin or hepcidin analogue in an amount sufficient to reduce the serum iron concentration of the subject. In some embodiments, administering the hepcidin or hepcidin analogue comprises administering the hepcidin or hepcidin analogue at an initial dose below the threshold dose to induce serum iron rebound. In some embodiments, the methods further comprise administering to the subject an additional dose of the hepcidin or hepcidin analogue. In some embodiments, the methods further comprise administering to the subject additional doses

(e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, , 12, 3, 14, 15, 16, 17, , 19, 20, 2 1, 22, 23, 24, 25, 26, 27, 28, 29, 30, 3 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 50, 60, 70, 80, 90, 100, 50, or 200 additional doses) of the hepcidin or hepcidin analogue. In some embodiments, the initial dose of the hepcidin or hepcidin analogue is from about 0 .1 mg to about 40 mg, preferably from about 1 mg to about 30 mg (e.g., from about 5 mg to about 30 mg, from about 10 mg to about 30 mg, from about 20 mg to about 30 mg, from about 1 mg to about 20 mg, from about 5 mg to about 20 mg, from about 1 mg to about 20 mg, from about 1 mg to about 10 mg, from about 5 mg to about 0 mg). In some embodiments, the initial dose of the hepcidin or hepcidin analogue is about 0 .1 mg, 0.5 mg, 1 rng, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 rng, 9 mg, 0 mg, rng, 12 mg, 13 mg,

4 mg, 15 mg, 16 mg, 7 mg, 18 mg, 19 mg, 20 mg, 2 1 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 2 8 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg or 40 mg. In some embodiments, the additional dose or doses of the hepcidin or hepcidin analogue is from about 0. mg to about 40 mg, such as from about 1 mg to about 3 mg (e.g.. from about 5 mg to about 30 mg, from about mg to about 30 mg, from about 20 mg to about 30 mg, from about 1 mg to about 20 mg, from about 5 mg to about 20 mg, from about 0 mg to about 20 mg, from about 1 mg to about 0 mg, from about 5 mg to about 0 mg). In some embodiments, the additional dose or doses of the hepcidin or hepcidin analogue is about 0.1 mg, 0.5 mg, i mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg,

9 mg, 10 mg, 1 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 rng, 20 mg, 2 1 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 3 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg or 40 mg. The additional doses described herein may be the same, higher, or lower than the initial dose. Methods described herein may include increasing the dose of the hepcidm or hepcidin analogue between one dose and a subsequent dose. Methods described herein may include decreasing the dose of the hepcidin or hepcidin analogue between one dose and a subsequent dose. Methods described herein may include increasing the frequency of administering the hepcidin or hepcidin analogue (e.g., from biweekly to weekly, or weekly to semi-weekly). Methods described herein may include decreasing the frequency of administering the hepcidin or hepcidin analogue (e.g., from semi-weekly to weekly, or from weekly to biweekly). In some embodiments, the method further comprises measuring the patient's serum iron level. In some embodiments, the method comprises adjusting or titrating the dose of administration in response to a subject's serum iron measurement. In some embodiments, the methods comprise increasing the dose or frequency at which the hepcidin or hepcidin analogue is administered if serum iron levels are above a predetermined target level. In some embodiments, the methods comprise decreasing the dose or frequency at which the hepcidin or hepcidin analogue is administered if serum iron levels are below a predetermined target level. In some embodiments, the additional doses are the same as the initial doses. Comparing the assessment of serum iron after administering a dose to the assessment made prior to administering the dose will indicate whether serum iron is increasing or decreasing as a result of the hepcidin or hepcidin analogue therapy. In some embodiments, the amount of hepcidin or a hepcidin analogue administered to the subject or in the formulation is about 0.1 mg to about 40 mg. In some embodiments, the hepcidin or hepcidin analogue is administered in an amount of between about 1 mg to about 30 mg. In some embodiments, the amount is about 1000 g, about 00 ug, about 1200 ug, about 300 ug, about 1400 ug, about 1500 ug, about 1600 g , about 1750 ,ug, about 1800 g, about 2000

µg, about 2 00 µg, about 2200 ug, about 2300 g , about 2400 g, about 2400 µg, about 2500 µg, about 2600 g, about 2700 ug, about 2800 , about 2900 ug, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 rng, about 9 mg, about 10 rng, about 1 mg, about 12 mg, about 3 mg, about 14 mg, about mg, about 16 mg, about 17 mg, about mg, about mg, about 20 mg, about 2 1 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg about 27 mg, about 28 mg, about 29 mg, or about 30 mg. In some embodiments, the amount of hepcidin or hepcidin analogue administered is at least about 1000 µg, about 1100 g, about 1200ug, about 300 ug, about 1400 ug, about 1500 ug, about 1600 g, about 1750 µg, about 1800 µg, about 2000 ug, about 2100 , about 2200 g, about 2300 ug, about 2400 µ , about 2400 , about 2500 ug, about 2600 µ , about 2700 g, about 2800 µg, about 2900 g, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 rng, about

8 mg, about 9 mg, about 10 mg, about 1 mg, about 12 mg, about 13 mg, about 14 mg, about

15 mg, about 16 mg, about mg, about 18 mg, about 19 mg or about 20 mg. In some embodiments, the amount of hepcidin or hepcidin analogue administered is no more than about 20 rrig, about 2 1 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg about 27 mg, about 28 mg, about 29 mg, or about 30 mg.

In some embodiments, the subject is administered an individual dose (e.g., a bolus) of the amount of the hepcidin or hepcidin analogue. In some embodiments, the subject is administered multiple doses (e.g., 2 , 3, 4, 5 or 6 doses) over a short period of time (e.g., 10 minutes, 2 0 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 8 hours, 19 hours, 20 hours, 2 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days) wherein the total amount of hepcidin or hepcidin analogue administered is in an amount sufficient to reduce the seram iron concentration of the subject without inducing a serum iron level rebound. In some embodiments, the hepcidin or a hepcidin analogue is administered to the subject once per day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, once every 7 days, once every 8 days, once every 9 days, once every 10 days, once every 11 days, once every 12 days, once every 13 days or once every 14 days. In some embodiments, the hepcidin or a hepcidin analogue is administered to the subject 1, 2, 3, 4, 5, 6, or 7 times per week. In some embodiments, the hepcidin or a hepcidin analogue is administered to the subject 1, 2, or 3 times per week. In some embodiments, the hepcidin or a hepcidin analogue is administered to the subject once a week. In some embodiments, the hepcidin or a hepcidin analogue is administered to the subject once every two weeks. In some embodiments, the amount of hepcidin or hepcidin analogue is administered as necessary. For example, in some embodiments, the amount of hepcidm or hepcidin analogue is administered when the subject's serum iron concentration elevates above a baseline serum iron concentration. In some embodiments, the hepcidin or hepcidin analogue is administered when the subject's transferrin saturation level rises above 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90%. In some embodiments, the methods comprise administering about 0.1to about 40 mg of hepcidin or hepcidin analogue to the subject each time it is administered. In some embodiments, the methods comprise administering about 1 to about 30 mg of hepcidin or hepcidin analogue to the subject each time it is administered. In some embodiments, about

100 g, about 200ug, about 300 fig, about 400 g , about 1500 g, about 600 g, about 750 fig, about 800 fig, about 1000 ug, about 1100 ug, about 1200ug, about 1300 µg, about 1400 f g, about 1500 ug, about 1600 g, about 1750 µg, about 1800 µg, about 2000 fig, about 2100 µg, about 2200 ug, about 2300 g, about 2400 µg, about 2400 µg, about 25 0 g, about 2600 g, about 2700 ug, about 2800 µg, about 2900 fig, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 1 mg, about mg, about 12 mg, about 3 mg, about 14 mg, about mg, about 6 mg, about 17 mg, about 1 mg, about 9 mg, about 20 mg, about 2 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg about 27 mg, about 28 mg, about 29 mg, or about 30 mg of the hepcidin or hepcidin analogue is administered to the subject each time it is administered. In some embodiments, at least about 1000 ug, about 00 g, about 1200ug, about 1300 ug, about 1400 ug, about 1500 ug, about 1600 ug, about 1750 ug, about 1800 ug, about 2000 g, about 2100 g, about 2200 µg, about 2300 ug, about 2400 fig, about 2400 ug, about 2500 ug, about 2600 ug, about 2700 ug, about 2800 µg, about 2900 fig, about 3 mg, about 4 mg, about 5 rng, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 0 mg, about mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 17 mg, about mg, about 9 mg or about 20 mg of the hepcidin or hepcidin analogue is administered to the subject each time it is administered. In some embodiments, no more than about 20 mg, about 2 1 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg about 27 mg, about 28 mg, about 29 mg, or about 30 mg of the hepcidin or hepcidin analogue is administered to the subject each time it is administered.

Therapeutic Methods In some aspects, provided herein are methods of treating and/or preventing iron overload in a subject, wherein the hepcidin or hepcidin analogue is administered at an amount sufficient to reduce the semm iron concentration of the subject without inducing a serum iron level rebound. In some embodiments, the method comprises administering to the subject pharmaceutical composition comprising hepcidin or a hepcidin analogue. In some embodiments, the subject has undergone iron chelation. In some embodiments, the subject has undergone phlebotomy therapy. In some embodiments, the subject is undergoing combination therapy with hepcidin or hepcidin analogue as well as iron chelation or phlebotomy therapy. The subject may have β-thalassernia, hemochromatosis, sickle cell disease, refractory anemia, or hemolytic anemia. The subject may be afflicted with hemochromatosis and the hemochromatosis may be hereditary hemochromatosis. The subject may have hemochromatosis and the hemochromatosis may be associated with hepatocarcinoma, cardiomyopathy, or diabetes. The subject may have anemia. Anemia may be, for example, a hemoglobinopathy, sideroblastic anemia, anemia associated with myelodysplastic syndrome (MDS), or a congenital anemia. The subject may have myelodysplastic syndrome (MDS). The subject may have hemoglobinopathy, sideroblastic anemia, or a congenital anemia. n some embodiments, the subject may have may be hepatocarcinoma, cardiomyopathy, or diabetes. Investigators have found that iron chelators can improve outcomes in the treatment of infectious disease, such as malaria. See Cabantchik et al., Iron chelators as anti-infectives; malaria as a paradigm, FEMS Immunology and Medical Microbiology, 26 (1999) 289-298; Gordeuk et al., Effect of Iron Chelation Therapy on Recovesy from Deep Coma in Children with Cerebral Maiana, N. Engl. J. Med. 1992, 327:1473-1477; Drakesmith, H . and Prentice, A., Viral infection and iron metabolism, Nat. Rev. Microbiol. 2008, 6:541-552; Iglesias- Osma et al., Iron metabolism and fungal infections in patients with haematological malignancies, J. Clin. Pathol. 1995, 48:223-225; B.J. Cherayil, The role of iron in the immune response to bacterial infection, Immunol. Res. 2011, 50:1-9. Accordingly, in some embodiments, the subject may have a viral, bacterial, fungal, or protist infection. In some embodiments, the subject may have a bacterial infection, and the bacteria is Escherichia coli, Mycobacterium (such as africanum,M. avium, M. tuberculosis, M . bovis, M. canetti, M. kansasii, M . leprae, M . lepromaiosis, or M . microti), Neisseria cinerea. Neisseria gonorrhoeae. Staphylococcus epidermidis. Staphylococcus aureus, or Streptococcus agalactiae. In some embodiments, the subject may have a fungal infection, and the fungus is Candida albicans. In some embodiments, the subject may have a protist infection, and the protist is Trypanosoma cruzi, Plasmodium (such as P. falciparum, . vivax, . ovale, or P. malariae), Trypanosoma brucei (such as T. bruce gamhiense or T. brucei rhodesiense), or Leishmania. The subject may have a viral, bacterial, fungal, or protist infection, and the viral, bacterial, fungal, or protist infection may be resistant to one or more agents for treating the viral, bacterial, fungal, or protist infection. The subject may have a bacterial infection and the bacterial infection may be tuberculosis. The subject may have Chagas disease, malaria, African sleeping sickness, or leishmaniasis. In some embodiments, the subject may have a viral infection, and the vims is hepatitis B, hepatitis C, or dengue virus. In some embodiments, the method may comprise the conjoint administration of 4- aminosalicyiic acid, aldesulfone, amikacin, amithiozone, bedaquiline, capreomycin, clofazimine, cycloserine, dapsone, delamanid, ethambutol, a fluoroquinolone, isoniazid, kanamycin, modified vaccinia Ankara 85A (MVA85A), morinamide, ofloxacin, pyrazinamide, recombinant Bacillus Calmette-Guerin 30 (rBCG30), rifampicin, rifater, streptomycin, terizidone, and/or thioacetazone to the subject. The method may comprise the conjoint administration of balofloxacin, cinoxacin, ciprofloxacin, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacm, enrofloxacin, fleroxacin, Fourth- generation, gatifioxacin, gemifloxacin, grepafloxacin, ibafloxacin, JNJ-Q2, ievofloxacin, lomefloxacin, marbofloxacin, moxifioxacin, nadifloxacin, nalidixic acid, nemonoxacin, norfloxacin, ofloxacin, orbifloxacin, oxolinic acid, pazufloxacin, pefloxacin, pipemidic acid, piromidic acid, prulifioxacin, rosoxacin, rafloxacm, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxaein, and/or trovafloxacin to the subject. n certain such embodiments, the subject may have tuberculosis and/or &Mycobacterium infection. The subject may have tuberculosis and the tuberculosis may be drug-resistant tuberculosis. In some embodiments, he subject may have tuberculosis and the tuberculosis may be multi-drug-resistant tuberculosis (MDR-T'B), extensively drag-resistant tuberculosis (XDR- TB), or totally drug-resistant tuberculosis (TDR-TB). The subject may have tuberculosis, and the tuberculosis may not be drug-resistant, multi-drag-resistant, extensively drug- resistant, or totally drag-resistant. The subject may have tuberculosis and/or a Mycobacterium infection and subject may be resistant to isoniazid, ethambutol, rifampicin, pyrazinamide, ofloxacin, one or more fluoroquinolones, amikacin, kanamycin, and/or capreomycin. In some embodiments, the method may comprise the conjoint administration of fluconazole, ketoconazoie, miconazole, and/or itraconazole to the subject. In certain such embodiments, the subject has Chagas disease and/or Trypanosoma cruzi infection, and the subject has may be resistant to one or more of fluconazole, ketoconazoie, miconazole, and/or itraconazole. The method may comprise the conjoint administration of fluconazole, benznidazole, and/or amphotericin B to the subject. In some embodiments, the subject may have African sleeping sickness and the method may comprise conjointly administering an arsenical and/or diamidine to the subject. The subject may have African sleeping sickness and/or Trypanosoma bruce infection, and subject may be resistant to arsenicals and/or diamidines. In some embodiments, the subject may have leishmaniasis and the methods herein may comprise conjointly administering a pentavalent antimonial to the subject. The subject may have leishmaniasis and the subject may be resistant to pentavalent antimonials. The methods may comprise conjointly administering amphotericin, amphotericin B, pentavalent antimonials, miltefosine, paromomycin, and/or fluconazole to the subject. In some embodiments, the subject may have malaria. The subject may have malaria and the malaria may be resistant to one or more agents for treating malaria. The subject may- have malaria, and the method may comprise conjoint administration of chioroquine, quinine, sulfadoxine-pyrimethamine, halofantrine, atovaquone, and/or mefloquine to the subject. The subject may have malaria, and the malaria may be resistant to one or more of chloroqume, quinine, sulfadoxine-pyrimethamine, halofantrine, atovaquone, and/or mefloquine. The subject may have a multidrug-resistant falciparum malana infection. The method may compri se the conjoint administration of one or more of proguanil, chlorproguanil, pyronaridine, lumefantrinel, mefloquine, dapsone, atovaquone, and/or artesunate to the subject. n some embodiments, the method may comprise the conjoint administration of artemisinin or an artemisinin derivative to the subject. The method may comprise the conjoint administration of artesunate, artemisinin, dihydro-artemisinin, artelinate, arteether, and/or artemether to the subject. In some embodiments, the hepcidin or hepcidin analogues can be administered in a variety of conventional ways. In some aspects, the hepcidin or hepcidin analogues are suitable for parenteral administration. These hepcidin or hepcidin analogues may be administered, for example, intraperitoneal!}', intravenously , intrarenaliy, or mtrathecaiiy. n some aspects, the hepcidin or hepcidin analogues are injected intravenously. In some embodiments, the hepcidin or hepcidin analogues may be administered topically, enterally, or parenteral!} . Hepcidin or hepcidin analogues may be administered subcutaneous!}', intravenously, intramuscularly, intranasal!}', by inhalation, ora!!y, sublingual!}', by buccal administration, topically, transdermal!y, or transmucosal!y. Hepcidin or hepcidin analogues may be administered by injection. In some embodiments, hepcidin or hepcidin analogues is administered by subcutaneous injection, orally, intranasal!}', by inhalation, or intravenously. In certain embodiments, the hepcidin or hepcidin analogues is administered by subcutaneous injection. In some embodiments, the subject may be a mammal. In some embodiments, the subject may be a rodent, lagomorph, feline, canine, porcine, ovine, bovine, equine, or primate. In certain embodiments, the subject is a human. In some embodiments, the subject may be a female or male. In some embodiments, the subject may be an infant, child, or adult. In some embodiments, the serum iron concentration of the subject is at least about 50 prior to administering the hepcidin or hepcidin analogue, such as at least about 55 ug/dL, at least about 60 ug/dL, at least about 65 g/dL, at least about 70 .g/dL , at least about 75 g dL, at least about 80 ug/dL, at least about 85 µg/dL, at least about 90 at least about 95 ug/dL, at least about 100 at least about 0 g dL, at least about 120 ug/dL, at least about 30 g/dL, at least about 140 fig/dL, at least about 50 g/dL, at least about 60 ug/dL, at least about 170 µg L, at least about 5 ug/dL, at least about 76 at least about 177 g/dL, at least about 0 µg/ , at least about 190 g dL, at least about 200 g dL, at least about 210 µg/ , at least about 220 ug/dL, at least about 230 g/dL, at least about 240 g dL, at least about 250 µg/dL, at least about 260 dL, at least about 270

g/ .. at least about 280 ug/dL, at least about 290 g dL, or at least about 300 ug/dL. The serum iron concentration of the subject may be about 50 g dL to about 500 µg/dL prior to administering the hepcidin or hepcidin analogue, such as about 55 ug/dL to about 500 µg/ , about 60 ug/dL to about 500 ug/dL, about 65 µ.g/ά to about 500 g/dL, about 70 g/dL to about 500 µg/dL, about 75 µg/dL to about 500 ug/dL, about 80 µg/dL to about 500 g/dL, about 85 ug/dL to about 500 ug/dL, about 90 ug/dL to about 500 g/dL, about 95 g/dL to about 500 g/dL, about 100 ug/dL to about 500 ug/dL, about 110 ug/dL to about 500 ug/dL, about 120 µ ά to about 500 ug/dL, about 130 ug/dL to about 500 µg/dL, about 140 to about 500 µg/dL, about 50 µg/dL to about 500 g dL, about 60 g/dL to about 500 µg/dL, about 170 ug/dL to about 500 g/dL, about 75 µg/dL to about 500 µg/dL, about 76 Ug/dL to about 500 ug/dL, about 77 µg/dL to about 500 µg/dL, about 1 0 µg/dL to about 500 µg/dL, about 90 µ d to about 500 ug/dL, about 200 µg/dL to about 500 ug/dL, about 210 µg/dL to about 500 g/dL, about 220 ug/dL to about 500 g/dL, about 230 ug/dL to about 500 ug/dL, about 240 ug/dL to about 500 ug/dL, about 250 ug/dL to about 500 ug/dL, about 260 ug/dL to about 500 ug/dL, about 270 ug/dL to about 500 µg/dL, about 280 to about 500 ug/dL, about 290 µg/dL to about 500 g dL, or about 300 g/dL to about 500 g/dL. In some embodiments, administering the hepcidin or hepcidin analogue to a subject decreases the serum iron concentration of the subject. In some embodiments, the serum iron concentration of the subject is less than about 200 g/dL following administration the hepcidin or hepcidin analogue, such as less than about 200 ug/dL, less than about 5 ug/dL, less than about 190 ug/dL, less than about 185 ug/dL, less than about 180 .g /'d L , less than about 175 µg L, less than about 70 jjg/dL, such as less than about 65 ,ug/dL, less than about 160 µg/dL, less than about 155 g/dL, less than about 150 g/dL, less than about 145 ug/dL, less than about 140 less than about 135 g/dL, such as less than about 130 ug/dL, less than about 125 }.ig/'dL, less than about 120 fig/'dL, less than about 15 g/dL, less than about 10 g/dL, or less than about 105 ug/dL. serum iron concentration of the subject is less than about 100 ug/dL following administration the hepcidin or hepcidin analogue, such as less than such as less than about 95 ug/dL, less than about 90 g/dL, less than about 85 pg/dL, less than about 80 µg/dL, less than about 75 pg/dL, less than about 70 ug/dL, such as less tha about 65 g/dL, less than about 60 less than about 55 ug/dL, less than about 50 g/dL, less than about 45 g/dL, less than about 40 g/dL, less than about 35 µg/dL, such as less than about 30 g/dL, less than about 25 g/dL, less than about 20 less than about 10 ug/dL, or less than about 5 µg/dL. In some embodiments, administering the hepcidin or hepcidin analogue may decrease the serum iron concentration of the subject for at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days or at least 7 days. For example, administering the hepcidin or hepcidin analogue may decrease the serum iron concentration of the subject by at least about 5 g/dL. Administering the hepcidin or hepcidin analogue may decrease the serum iron concentration of the subject by at least about 5 µ /ά1, for at least 4 hours, at least 6 hours, at least 8 hours, at least 12 hours, at least 24 hours, or at least 48 hours. Administering the hepcidin or hepcidin analogue may decrease the serum iron concentration of the subject by at least about 5 g/dL for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days. Administering the hepcidin or hepcidin analogue may decrease the serum iron concentration of the subject by at least about 5%, such as at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% or at least about 5 %. Administering the hepcidin or hepcidin analogue may decrease the serum iron concentration of the subject by at least about 5% for at least 4 hours, at least 6 hours, or at least 12 hours. Administering the hepcidin or hepcidin analogue may decrease the serum iron concentration of the subject by at least about 5%, 10% or 15% for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days. In some embodiments, the subject has a serum hepcidin concentration of less than about 1000 ng/mL prior to administering the hepcidin or hepcidin analogue, such as less than about 900 ng/mL, less than about 800 ng/mL, less than about 700 ng/mL, less than about 600 ng/mL, less than about 500 ng/mL, less than about 400 ng/mL, less than about 300 ng/mL, less than about 200 ng/mL, less than about 0 ng/mL, less than about 90 ng/mL, less than about 80 ng/mL, less than about 70 ng/mL, less than about 60 ng/mL, less than about 50 ng/mL, less than about 40 ng/mL, less than about 30 ng/mL, less than about 20 ng/mL, or less than about ng/mL The subject may have a serum hepcidin concentration of about 1 ng/mL to about 000 ng/mL prior to administering the hepcidin or hepcidin analogue, such as about 1 ng/mL to about 900 ng mL, about 1 ng/mL to about 800 ng/mL, about 1 ng/mL to about 700 ng/mL, about 1 ng/mL to about 600 ng/mL, about 1 ng/mL to about 500 ng/mL, about 1 ng/mL to about 400 ng/mL, about 1 ng/mL to about 300 ng/mL, about 1 ng/mL to about 200 ng/mL, about 1 ng/mL to about 100 ng/rnL, about 1 ng/mL to about 90 ng/mL, about 1 ng/mL to about 80 ng/mL, about 1 ng/mL to about 70 ng/mL, about 1 ng/mL to about 60 ng/mL, about 1 ng/mL to about 50 ng/mL, about 1 ng/mL to about 40 ng/mL, about 1 ng/mL to about 30 ng/mL, about 1 ng/mL to about 20 ng/mL, or about 1 ng/mL to about 10 ng/mL. In some embodiments, the subject has a serum ferritin concentration greater than about 10 ng/mL prior to administering the hepcidin or hepcidin analogue, such as greater than about 20 ng/mL, greater than about 30 ng/mL, greater than about 40 ng/mL, greater than about 5 ng/mL, greater than about 60 ng/mL, greater than about 70 ng/mL, greater than about 80 ng/mL, greater than about 90 ng/mL, greater than about 0 ng/mL, greater than about 200 ng/mL, greater than about 300 ng/mL, greater than about 400 ng/mL, greater than about 500 ng/mL, greater than about 600 ng/mL, greater than about 700 ng/mL, greater than about 800 ng/mL, greater than about 900 ng/mL, greater than about 1000 ng/mL, greater than about 2000 ng/mL, greater than about 3000 ng/mL, greater than about 4000 ng/mL, greater than about 5000 ng/mL, greater than about 6000 ng/rnL, greater than about 7000 ng/mL, greater than about 8000 ng/mL, greater than about 9000 ng/mL, or even greater than about 10 ug/mL. The subject may have a serum ferritin concentration of about 10 ng/mL to about 100 ug/mL prior to administering hepcidin or hepcidin analogue, such as about 20 ng/mL to about 100 ug/mL, about 30 ng/mL to about 0 ug/mL, about 40 ng/mL to about 100 ug/mL, about 50 ng/mL to about 100 ^ig/mL, about 60 ng/mL to about 100 ug/mL, about 70 ng/mL to about 100 ug/mL, about 80 ng/mL to about 100 g/mL, about 90 ng/mL to about 100 g/mL, about 0 ng/mL to about 100 ug/mL, about 200 ng/mL to about 100 .ug/mL, about 300 ng/mL to about 100 µg/mL, about 400 ng/mL to about 100 ug/mL, about 500 ng/mL to about 100 ng/mL, about 600 ng/mL to about 0 g/mL, about 700 ng/mL to about 100 µg/mL, about 800 ng/mL to about 100 ug/mL, about 900 ng/mL to about 100 ug/mL, or about 00 ng/mL to about 100 jig/mL. The subject may have a serum ferritin concentration of about ng/mL to about 20 .ug/mL prior to administering hepcidin or hepcidin analogue, such as about 20 ng/mL to about 20 g/mL, about 30 ng/mL to about 20 .ug/mL, about 40 ng mL to about 20 ug/mL, about 5 ng/mL to about 20 g/mL, about 60 ng/mL to about 20 g/mL, about 70 ng/mL to about 20 ug/mL, about 80 ng/mL to about 20 ug/mL, about 90 ng/mL to about 20 .ug/mL, about 100 ng/mL to about 20 g/mL, about 200 ng/mL to about 20 ug/mL, about 300 ng/mL to about 20 ^ig/mL, about 400 ng/mL to about

20 }.ig/'mL, about 500 ng/mL to about 20 g/mL, about 600 ng/mL to about 20 g/mL, about 700 ng/mL to about 20 ug/mL, about 800 ng/mL to about 20 about 900 ng/mL to about 20 ug/mL, or about 00 ng/mL to about 20 µg mL. In some embodiments, the subject has a serum ferritin concentration of less than about 10 g /ffiL prior to administering hepcidin or hepcidin analogue, such as less than about 000 ng/mL, less than about 900 ng/mL, less than about 800 ng/mL, less than about 700 ng/mL, less than about 600 ng/mL, less than about 500 ng/mL, less than about 400 ng/mL, less than about 300 ng/mL, less than about 200 ng/mL, less than about 0 ng/mL, less than about 90 ng/mL, less than about 80 ng/mL, less than about 70 ng/mL, less than about 60 ng/mL, less than about 50 ng/mL, less than about 40 ng/mL, less than about 30 ng/mL, less than about 20 ng/mL, or less than about 10 ng/mL. The subject may have a serum ferritin concentration of about 1 ng/mL to about 1000 ng/mL prior to administering the hepcidin or hepcidin analogue, such as about 1 ng/mL to about 900 ng/mL, about 1 ng/mL to about 800 ng mL, about 1 ng/mL to about 700 ng/mL, about 1 ng/mL to about 600 ng/mL, about 1 ng/mL to about 500 ng/mL, about 1 ng/mL to about 400 ng/mL, about 1 ng/mL to about 300 ng/mL, about 1 ng/mL to about 200 ng/mL, about 1 ng/mL to about 00 ng/mL, about 1 ng/mL to about 90 ng/mL, about 1 ng/mL to about 80 ng/mL, about 1 ng/mL to about 70 ng/mL, about 1 ng mL to about 60 ng/mL, about 1 ng/mL to about 50 ng/mL, about 1 ng/mL to about 40 ng/mL, about 1 ng/mL to about 30 ng/niL, about 1 ng/mL to about 20 ng/mL, or about 1 ng/mL to about 10 ng/mL. In some embodiments, administering the hepcidin or hepcidin analogue decreases the serum ferritin concentration of the subject. For example, administering hepcidin or hepcidin analogue may decrease the serum ferritin concentration of the subject to about less than 100 ng/mL after to administering the hepcidin or hepcidin analogue to the subject, such as about less than 90 ng/mL, about less than 85 ng/mL, about less than 80 ng/mL, about less tha 75 ng/mL, about less than 70 ng/mL, about less than 65 ng/mL, about less than 60 ng/mL, or about less than 55 ng/mL. In some embodiments, administering hepcidin or hepcidin analogue may decrease the serum ferritin concentration of the subject to about less than 50 ng/mL after to administering the hepcidin or hepcidin analogue to the subject, such as about less than 45 ng/mL, about less than 40 ng/mL, about less than 35 ng/mL, about less than 30 ng/mL, about less than 25 ng/mL, about less than 20 ng/mL, or about less than 5 ng/mL. Administering hepcidin or hepcidin analogue may decrease the serum ferritin concentration of the subject by at least 10 ng/mL, at least about 2 0 ng/mL, at least about 30 ng/mL, at least about 40 ng/mL, at least about 50 ng/mL, at least about 60 ng/mL, at least about 70 ng/mL, at least about 80 ng/mL, at least about 90 ng/mL, or at least about 100 ng/mL. In some embodiments, the subject has a total body iron content of about 40 to about 50 mg/kg prior to administering the hepcidin or hepcidin analogue. The subject may have a total body iron content greater than about 50 mg/kg prior to administering hepcidin or hepcidin analogue, such as greater than about 55 mg/kg, greater than about 60 mg/kg, greater than about 65 mg/kg, or greater than about 70 mg/kg. In some embodiments, the subject has a total body iron content of less than 25 mg/kg after to administering the hepcidin or hepcidin analogue to the subject, such as less than 24 mg/kg, such as less than 23 mg/kg, such as less than 22 mg/kg, such as less than 2 mg/kg, such as less than 20 mg/kg, such as less than 19 mg/kg, such as less than 18 mg/kg, such as less than 17 mg/kg, such as less than

6 mg/kg, such as less than 5 mg/kg, such as less than 14 mg/kg, such as less than 3 mg/kg, such as less than 12 mg/kg, such as less than mg/kg, such as less than 10 mg/kg, such as less than 9 mg/kg, such as less than 8mg/kg, such as less than 7 mg/kg, such as less than 6mg/kg, or such as less than 5 mg/kg. In some embodiments, the subject has a transferrin saturation percentage greater than about 50% prior to administering hepcidin or hepcidin analogue, such as greater than about 55%, greater than about 60%, greater than about 65%, greater than about 70%, greater than about 75%, greater than about 80%, greater than about 85%, greater than about 90%, greater than about 95%. The subject may have a transferrin saturation percentage of about 5 % to about 99% prior to administering hepcidin or hepcidin analogue, such as about 55% to about 99%, about 60% to about 99%, about 65% to about 99%, about 70% to about 99%, about 75% to about 99%, about 80% to about 99%, about 85% to about 99%, about 90% to about 99% or about 95% to about 99%. In some embodiments, administering the hepcidin or hepcidm analogue decreases the transferrin saturation percentage of the subject. For example, administering hepcidin or hepcidin analogue to a subject may decrease the transferrin saturation percentage of the subject to between 15% and 50%, to between 15% and 25%, to between 20% and 50%, to between 20% and 40%, to between 25% and 50%, to between 25% and 40%, to between 30% and 50% or to between 30% and 40%. In certain particular embodiments, the method comprises subcutaneously administering an initial 5-mg dose of hepcidm followed by subsequent weekly doses. The subsequent doses can be increased or decreased to determine the optimal dose, based on the patient's clinical response and/or predetermined target parameters. For example, the weekly dose can be increased up to about 20 rng (e.g., by raising the dose per administration up to about 10 mg and increasing the dosing frequency up to twice weekly) or even up to about 40 mg or reduced down to about 1 mg (e.g., by lowering the dose per administration and/or decreasing the dosing frequency down to biweekly). For example, the dose of hepcidin can be titrated to achieve a TSAT level from 20% to 50%. n certain preferred embodiments, the subject has hemochromatosis, such as hereditary hemochromatosis, or beta-thalassemia.

EXEMPLIFICATION Example I : Serum iron rebound followi s administration of a threshold level of Hepcidin Patients were recruited for a multi-day study to observe serum iron levels following administration of hepcidin. All patients who were recruited had either refractory or hemolytic anemia or hemochromatosis. Patients are divided into cohorts and subsequently treated with hepcidin. Treatment consisted of a single subcutaneous (SC) dose of hepcidin on

Day 1. Dose escalation with new cohorts occurred only after the patients at each dose level had been observed for a minimum of 3 days and no drug related toxicity had been observed.

The starting dose level was 1 mg given via SC injection on Day 1. Doses ranged from 1 mg to 3 mg. Patient cohorts and dosing can be found in Table 1: Table 1; Dose Escalation:

Patients were admitted to the research unit the day before the administration of study drug and discharged following assessments 48 hours post dose. Serum iron, ferritin, transferrin, total iron binding capacity, and unsaturated iron binding capacity were measured on Day 1 (baseline) and Day 7 (end of study). Serum iron was also measured at 2, 4, 8, 24, and 48 hours post dosing. The percent change in Serum Iron from baseline to hour 8 is provided in Table 2.

Table 2: Change in serum iron at § hours

As seen in Figure I, a dose-dependent, statistically significant reduction in serum iron was observed (p-0.009 for dose response). At the 20 mg dose level, hepcidin reduced serum iron by 55 7% from baseline to hour 8 (p=0.001; not adjusted for potential regression to the mean effect). As seen in Figure 2, for subjects administered 1 mg, 5 mg, 10 mg or 20 mg of hepcidin, serum iron had not returned to baseline through day 7 (18.0% reduction from baseline to the end of day 7). Counterintuitively, subjects administered at least 30 mg of hepcidin experienced a rebound effect which resulted in above-baseline serum iron levels within 48 hours of treatment.

Example 2: Hepcidin Administration in Patients at Risk for Iron Overload Disorders Eighteen patients at risk for iron overload disorders (i.e., refractory or hemolytic anemia or hemochromatosis) received one or two 1-mL subcutaneous injections to achieve the desired dose level ( 1 mg, 5 mg, 10 g, 20 mg, or 30 mg). Hepcidin concentration ranged from 1 to mg/mL. A decrease in serum iron levels compared to baseline was generally observed in all five dose groups. Mean maximum percentage reductions per dose group occurred at 8 hours post-dose and reached 58% the 20-mg dose group. A significant dose response was present, with greater decrease in serum iron at higher doses. The serum iron reduction was sustained up to Day 8 in most patients. Decreases in ferritin, total iron binding capacity (TIBC), transferrin, and TSAT% leve s were also observed from Baseline (pre-dose) to Day 8 End of Study (EOS). No anti-drug antibodies were detected. Example 3: Hepcidin Administration in Healthy Subjects This study enrolled 32 healthy adult subjects in 4 dose groups of 8 subjects per cohort, with 6 subjects assigned to hepcidin treatment and 2 subjects assigned to placebo in each cohort. The starting dose was 5 mg of hepcidin or placebo; subsequent dose groups received 10 mg, 20 mg, and 30 mg, respectively. Subjects received between one and three 1- mL subcutaneous (SC) injections to deliver the desired dose level. Hepcidin concentration was either 5 rng/rnL or 10 mg/mL. For data analysis purposes, placebo subjects for all cohort groups were pooled. A decrease in serum iron levels compared to baseline was observed in all four dose groups, with mean maximum reduction of 33% to 65% at -hours post dose. Serum iron levels returned to baseline before 48 hours. A significant dose response was observed, with larger reductions in serum iron generally associated with increases in dose up to 20 mg. There was no apparent difference in the maximum reduction between the 20 and 30 mg dose levels. Ferritin, total iron binding capacity (TIBC), transferrin, and TSAT% were increased from baseline at Day 8 for a l treatment groups. Unsaturated iron binding capacity (UIBC) levels showed no trends in changes from baseline at Day 8. No anti-drug antibodies were detected.

Example 4: Hepcidin administration in patients with hereditary hemochromatosis One hundred and twenty patients with hereditary hemochromatosis are administered hepcidin. Patients are randomized 2:1 to Hepcidin or Placebo. Patients are administered hepcidin or placebo subcutaneously for 12 weeks. All patients receive standard of care therapeutic phlebotomy within 0 to 14 days after the first dose of study drug. Initial dose of hepcidin is 5 mg. Patient dose is increased or decreased to determine the optimal dose, considering efficacy and safety parameters. The maximum weekly dose is 20 mg while the minimum weekly dose is 1 mg. n addition, the dose amount of hepcidin is titrated in order to achieve the desired TSAT level (20% to 50%) or maximally tolerated dose. TSAT levels are measured weekly during the treatment period. Patients are dosed once weekly dependent on the patient s previous TSAT reading in relation to the next planned dose.

Example 5: Hepcidin administration in patients with bela-thalassemia One hundred patients receive hepcidin either as immediate treatment or as deferred treatment. The deferred treatment group includes an on-study observation period of standard of care (SOC) therapy being administered at study entry. Eligible patients are randomized in a : ratio to treatment group A or B : Group A (Deferred Therapy)

• A : 26 weeks SOC A2: 26 weeks hepcidin and SOC Group B (Immediate Therapy) • B : 52 weeks hepcidin and SOC Patients in Group A receive SOC and observation for 26 weeks followed by hepcidin plus SOC and observation for 26 weeks. Patients in Group B receive hepcidin plus SOC and observation for 52 weeks. Patients are dosed with hepcidin (administered SC) for 26 weeks (Group A) or 52 weeks (Group B). The initial dose of hepcidin is 5 mg. The maximum weekly dose is 40 mg while the minimum weekly dose is 1 mg. A patient may have their dose increased or decreased to determine the proper dose, considering efficacy and safety parameters. The dose amount of hepcidin is titrated in order to achieve the desired TSAT level (<50% and >20%) or maximally tolerated dose. During the treatment period, TSAT levels will be measured at each of the first 4 weeks and at 3- to 4-week intervals thereafter. Patients are dosed once weekly dependent on the patient s most recent TSAT% reading in relation to the next planned dose; but for patients who require more or less frequent dosing, the schedule can be as often as twice weekly or as few as every other week. What is claimed is:

1. A method of treating or preventing iron overload in a subject and/or reducing serum iron level in a subject comprising administering to the subject hepcidin or a hepcidin analogue, wherein the hepcidin or hepcidin analogue is administered in an amount sufficient to reduce the serum iron concentration of the subject without inducing a serum iron level rebound.

2 The method of claim , wherein the hepcidin or hepcidin analogue is hepcidin.

3. The method of claim 1 or claim 2, wherein the amount is between about 0. mg and about 40 mg of the hepcidin or hepcidin analogue.

4. The method of any one of the preceding claims, wherein the amount is between about 1 mg and about 30 mg of the hepcidin or hepcidin analogue.

5. Tire method of any one of claims 1to 4, wherein the amount is an amount of hepcidin or hepcidin analogue sufficient to reduce the transferrin saturation level in the subject to between 20% and 50%.

6. The method of claim 5, wherein the amount is an amount sufficient to reduce the transferrin saturation level in the subject to between 20% and 40%.

7. The method of any one of the preceding claims, wherein prior to administration the subject has a transferrin saturation level of at least 50%.

8. The method of claim 7, wherein prior to administration the subject has a transferrin saturation level of at least 90%.

9. The method of any one of the preceding claims, wherein the hepcidin or hepcidin analogue administered is at least 90% monomer.

10. The method of any one of the preceding claims, wherein administering the hepcidin or hepcidin analogue comprises administering the hepcidin or hepcidin analogue at about twice a week, once a week, once every 10 days or once every 2 weeks.

. The method of claim , wherein administering the hepcidin or hepcidin analogue comprises administering the hepcidin or hepcidin analogue about once a week. 12. The method of claim or 11, wherein about 0.1 mg to about 40 mg of the hepcidin or hepcidin analog is administered each time the hepcidin or hepcidin analogue is administered.

13. The method of claim 12, wherein between about 1 ng and about 30 mg of hepcidin or hepcidin analogue is administered at each dose.

14. The method of claim or claim 13, wherein about 1 mg of hepcidin or hepcidin analogue is administered at each dose.

15. The method of claim 12 or claim 13, wherein about 5 mg of hepcidin or hepcidin analogue is administered at each dose.

16. The method of claim 12 or claim 13, wherein about 10 mg of hepcidin or hepcidin analogue is administered at each dose.

. The method of claim 12 or claim 3, wherein about 5 mg of hepcidin or hepcidin analogue is administered at each dose.

8. The method of claim 12 or claim 13, wherein about 20 mg of hepcidin or hepcidin analogue is administered at each dose.

1 . The method of claim 2 or claim 13, wherein about 25 mg of hepcidin or hepcidin analogue is administered at each dose.

20. The method of claim 12 or claim 3, wherein about 30 mg of hepcidin or hepcidin analogue is administered at each dose.

2 1. The method of claim , wherein about 35 mg of hepcidin or hepcidin analogue is administered at each dose.

22. The method of claim 12, wherein about 40 mg of hepcidin or hepcidin analogue is administered at each dose.23. The method of any one of claims 1to 22, wherein the hepcidin or hepcidin analogue is administered subcutaneously, intravenously, intramuscularly, mtranasally, by inhalation, orally, sublingual!} , by buccal administration, topically, transdermally, or transmucosally.

24. The method of any one of claims 1 to 23, wherein the hepcidin or hepcidin analogue is administered by injection. 25. The method of claim 24, wherein the hepcidin or hepcidin analogue is administered by subcutaneous injection.

26. The method of any one of claims 1to 25, wherein the subject has β-thalassemia, hemochromatosis, sickle cell disease, or anemia, such as refractory anemia, or hemolytic anemia.

27. The method of claim 26, wherein the subject has β-thalassemia.

28. The method of claim 26, wherein the subject has hemochromatosis.

29. Tire method of claim 28, wherein the subject has hereditary hemochromatosis.

30. The method of claim 26, wherein the subject has anemia and the anemia is a hemoglobinopathy, sideroblastic anemia, anemia associated with myelodysplastic syndrome (MDS), or a congenital anemia.

31. The method of any one of claims 1to 25, wherein the subject has liver disease, cardiomyopathy, or diabetes.

32. The method of claim 3 , wherein the liver disease is liver cancer.

33. The method of any one of claims 1 to 25, wherein the subject has a viral, bacterial, fungal, or protist infection.

34. Tire method of claim 33, wherein the subject has a bacterial infection, and the bacteria is Escherichia coll, Neisseria cinerea. Neisseria gonorrhoeae. Staphylococcus epidermidis, Staphylococcus aureus, or Streptococcus agalactiae.

35. The method of claim 34, wherein the subject has a fungal infection, and the fungus is Candida albicans.

36. Tire method of claim 35, wherein the subject has a protist infection, and the protist is Trypanosoma cruzi, Plasmodium (such as P.falciparum, P. vivax, P. ovale, or P. malariae), Trypanosoma brucei (such as T. brucei gambiense or T. brucei rhodesiense), or Leishmania.

37. The method of claim 33, wherein the subject has a viral infection, and the virus is hepatitis B, hepatitis C, or dengue virus.

38. Tire method of any one of the preceding claims, wherein the subject is a mammal .

39. The method of claim 38, wherein the subject is a human. 40. The method of claim 39, wherein the subject has a serum hepcidin concentration of less than about 0 ng/mL prior to administering the hepcidin or hepcidin analogue to the subject.

41. The method of claim 40, wherein the subject has a semm hepcidin concentration of less than 50 ng/mL prior to administering the hepcidm or hepcidin analogue to the subject.

42. The method of any one of claims 38 to 41, wherein the subject has a serum ferritin concentration greater than 00 ng/mL prior to administering the hepcidin or hepcidin analogue to the subject.

43. The method of any one of claims 3 to 42, wherein the subject has a serum ferritin concentration greater than 200 ng/mL prior to administering the hepcidin or hepcidin analogue to the subject

44. The method of any one of claims 38 to 43, wherein the subject has a serum ferritin concentration greater than 300 ng/mL prior to administering the hepcidin or hepcidin analogue to the subject.

45. The method of any one of claims 38 to 44, wherein the subject has a serum ferritin concentration greater than 1000 ng/mL prior to administering the hepcidin or hepcidin analogue to the subject

46. The method of any one of claims 38 to 41, wherein the subject has atotal body iron content of about 40 to about 50 mg/kg prior to administering the hepcidin or hepcidin analogue to the subject.

47. The method of any one of claims 38 to 41, wherein the subject has a total body iron content greater than 50 mg/kg prior to administering the hepcidin or hepcidin analogue to the subject.

48. The method of claim 47, wherein the subject has a total body iron content greater than 60 mg/kg prior to administering the hepcidin or hepcidin analogue to the subject.

49. The method of any one of claims 38 to 41, wherein the serum iron concentration of the subject is at least about 100 ug/dL prior to administering the hepcidin or hepcidin analogue to the subject

50. The method of claim 49, wherein the serum iron concentration of the subject is at least about 200 g/ L prior to administering the hepcidin or hepcidin analogue to the subject. 5 . The method of any one of claims 38 to 4 , wherem the transferrin saturation of the subject is greater than about 50% prior to administering the hepcidin or hepcidin analogue to the subject.

52. The method of claim 51, wherein the transferrin saturation of the subject is greater than about 90% prior to administering the hepcidin or hepcidin analogue to the subject.

53. The method of claim 38 or claim 39, wherein the subject has a serum hepcidin concentration of more than about 25 ng/mL following administration the hepcidin or hepcidin analogue to the subject.

54. Tire method of claim 38 or claim 39, wherein the subject has a serum hepcidin concentration of more than about 50 ng/mL following administration of the hepcidin or hepcidin analogue to the subject.

55. The method of claim 38 or claim 39, wherein the subject has a serum ferritin concentration less than 100 ng/mL following administration of the hepcidin or hepcidin analogue to the subject.

56. The method of claim 38 or claim 39, wherein the subject has a serum ferritin concentration less than 50 ng/mL following administration the hepcidin or hepcidin analogue to the subject.

57. The method of claim 56, wherein the subject has a total body iron content of less than 25 mg/kg following administration of the hepcidin or hepcidin analogue to the subject.

58. The method of claim 38 or claim 39, wherein the subject has a total body iron content less than 15 mg/kg following administration the hepcidin or hepcidin analogue to the subject.

59. The method of claim 58, wherein the subject has a total body iron content less than mg/kg following administration the hepcidin or hepcidin analogue to the subject.

60. Tire method of claim 38 or claim 39, wherein the serum iron concentration of the subject is less than about 200 following administration the hepcidin or hepcidin analogue to the subject.

6 . The method of claim 60, wherein the serum iron concentration of the subject is less than about 0 ,ug/dL following administration the hepcidin or hepcidin analogue to the subject. 62. The method of claim 38 or claim 39, wherem the transferrin saturation of the subject is decreased to between 15% and 50% following administration the hepcidin or hepcidin analogue to the subject.

63. The method of claim 62, wherein the transferrin saturation of the subject is decreased to between 20% and 40% following administration the hepcidin or hepcidin analogue to the subject.

64. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has at least 60% sequence homology to SEQ D NO .

65. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ D NO 1.

66. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ D NO 1.

67. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has at least 60% sequence homology to SEQ ID NO 2.

68. The method of any one of claims 1 to 63, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 2.

69. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 2.

70. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has at least 60% sequence homology to SEQ ID NO 3.

7 . The method of any one of claims I to 63, wherein the hepcidin or hepcidin analogue has at least 80%> sequence homology to SEQ ID NO 3.

72. The method of any one of claims I to 63, wherein the hepcidin or hepcidin analogue has 00% sequence homology to SEQ ID NO 3.

73. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has at least 60% sequence homology to SEQ ID NO 4.

74. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 4.

75. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 4.

76. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has at least 60% sequence homology to SEQ ID NO 5. 77. The method of any one of claims 1 to 63, wherein the hepcidin or hepcidin analogue comprises at least 80% of SEQ ID NO 5.

78. The method of any one of claims 1 o 63, wherein the hepcidin or hepcidin analogue has 00% sequence homology to SEQ ID NO 5.

79. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 6.

80. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 6.

81. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 7 .

82. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has 00% sequence homology to SEQ ID NO 7.

83. The method of any one of claims 1to 63, wherem the hepcidin or hepcidm analogue has at least 80% sequence homology to SEQ ID NO 8.

84. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has 00% sequence homology to SEQ ID NO 8.

85. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 9.

86. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has 00% sequence homology to SEQ ID NO 9

87. The method of any one of claims 1 to 63, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 10.

88. The method of any one of claims 1to 63, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 10.

89. A method of treating or preventing iron overload in a subject and/or reducing serum iron level in a subject, comprising administering a hepcidin or hepcidin analogue at an initial dose at or below 40 mg thai is sufficient to reduce the serum iron concentration of the subject.

90. The method of claim 89, wherein the initial dose is from about 0.1 mg to about 40 mg of the hepcidin or hepcidin analogue.

91. The method of claim 90, wherein the initial dose is from about 1 mg to about 30 mg of the hepcidin or hepcidin analogue. 92. The method of claim 90, wherein the initial dose is about 1 mg of the hepcidin or hepcidin analogue.

93. The method of claim 90, wherein the initial dose is about 2.5 mg of the hepcidin or hepcidin analogue.

94. The method of claim 90, wherein the initial dose is about 5 mg of the hepcidin or hepcidin analogue.

95. The method of claim 90, wherein the initial dose is about mg of the hepcidin or hepcidin analogue.

96. The method of claim 90, wherein the initial dose is about 5 mg of the hepcidin or hepcidin analogue.

97. The method of claim 90, wherein the initial dose is about 20 mg of the hepcidin or hepcidin analogue.

98. The method of claim 90, wherein the initial dose is about 25 mg of the hepcidin or hepcidin analogue.

99. The method of claim 90, wherein the initial dose is about 30 mg of the hepcidin or hepcidin analogue.

100. The method of claim 90, wherein the initial dose is about 35 mg of the hepcidin or hepcidin analogue.

10 . The method of claim 90, wherein the initial dose is about 40 mg of the hepcidin or hepcidin analogue.

102. The method of any one of claims 89 to 101, wherein the initial dose is sufficient to reduce the transferrin saturation level in the subject to between 20% and 50%.

103. Hie method of claim 102, wherein the initial dose is sufficient to reduce the transferrin saturation level in the subject to between 20% and 40%.

104. The method of any one of claims 89 to 103, wherein prior to administration the subject has a transferrin saturation level of at least 50%.

105. The method of claim 104, wherein prior to administration the subject has a transferrin saturation level of at least 90%. 06. The method of any one of claims 89 to 105, wherein the hepcidin or hepcidin analogue is hepcidin.

107. The method of any one of claims 89 to 106, wherein the hepcidin or hepcidin analogue administered is at least 90% monomer.

108. The method of any one of claims 89 to 107, further comprising administering to the subject one or more additional doses of the hepcidin or hepcidin analogue.

109. The method of any one of claims 89 to 108, wherein administering the hepcidin or hepcidin analogue comprises administering additional doses of the hepci din or hepcidin analogue at a frequency of about twice a week, once a week, once every 0 days or once every 2 weeks.

10. The method of claim 109, wherein administering the hepcidin or hepcidin analogue comprises administering the hepcidin or hepcidin analogue about once a week.

111. The method of claim 9, wherein administering the hepcidin or hepcidin analogue comprises administering the hepcidin or hepcidin analogue about twice a week.

112. The method of any one of claims 1 9 to 111, wherein each additional dose is from about 0.1 mg to about 40 mg of hepcidin.

3. The method of claim 112, wherein each additional dose is from about 1 mg to about 30 mg of hepcidin or hepcidin analogue.

114. The method of any one of claims 90 to 113, wherein each additional dose is from about 0.2 mg to about 40 mg of hepcidin or hepcidin analogue.

115. The method of claim 114, wherein each additional dose is from about 1 ng to about 3 mg of hepcidm or hepcidin analogue.

6 . The method of claim 4, wherein each additional dose is about 2.5 mg of hepcidin or hepcidin analogue.

1 7. The method of claim 114, wherein each additional dose is about 5 mg of hepcidin or hepcidin analogue.

18. The method of claim 14, wherein each additional dose is about 10 mg of hepcidin or hepcidin analogue is administered at the additional dose(s). 119. The method of claim 4, wherein each additional dose is about mg of hepcidin or hepcidm analogue.

120. The method of claim 4, wherein each additional dose is about 20 mg of hepcidin or hepcidin analogue.

121. The method of claim 114, wherein each additional dose is about 25 mg of hepcidin or hepcidin analogue.

122. The method of claim 4, wherein each additional dose is about 30 mg of hepcidm or hepcidin analogue.

123. The method of claim 4, wherein each additional dose is about 30 mg of hepcidin or hepcidin analogue.

124. The method of claim 114, wherein each additional dose is about 35 mg of hepcidin or hepcidin analogue.

125. The method of claim 14, wherein each additional dose is about 40 mg of hepcidin or hepcidin analogue.

126. The method of any one of claims 9 to 25, wherein each additional dose is the same as the initial dose.

127. The method of any one of claims 109 to 125, wherein each additional dose is higher than the initial dose.

128. The method of any one of claims 109 to 127, further comprising increasing the frequency of administering the additional doses.

129. The method of any one of claims 109 to 127, further comprising decreasing the frequency of administering the additional doses.

130. The method of any one of claims 89 to 129, wherein the method further comprises measuring the patient's seram iron level.

131. The method of claim 130, further comprising increasing the dose or the frequency in response to the measured serum iron level.

32. The method of claim 130, further comprising decreasing the dose or the frequency in response to the measured serum iron level. 33. The method of any one of claims 89 to 132, wherein the hepcidin or hepcidin analogue is administered subcutaneously, intravenously, intramuscularly, intranasally, by inhalation, orally, sublingual!}', by buccal administration, topically, transdermaliy, or transmucosaily.

134. The method of any one of claims 89 to 132, wherein the hepcidin or hepcidin analogue is administered by injection.

135. The method of claim 134, wherein the hepcidin or hepcidin analogue is administered by subcutaneous injection.

136. The method of any one of claims 89 to 135, wherein the subject has β-thalassemia, hemochromatosis, or anemia, such as refractory anemia, or hemolytic anemia.

37. The method of claim 136, wherein the subject has β-thalassemia.

138. The method of claim 136, wherein the subject has hemochromatosis.

139. The method of claim 38, wherein the subject has hereditary hemochromatosis.

140. The method of claim 139, wherein the subject has anemia and the anemia is a hemoglobinopathy, sideroblastic anemia, anemia associated with myelodysplastic syndrome (MDS), or a congenital anemia.

141. The method of any one of claims 89 to 140, wherein the subject has liver disease, cardiomyopathy, or diabetes.

142. The method of claim 141, wherem the liver disease is liver cancer.

143. The method of any one of claims 89 to 142, wherein the subject has a viral, bacterial, fungal, or protist infection.

144. The method of claim 43, wherein the subject has a bacterial infection, and the bacteria is Escherichia coll, Neisseria cinerea. Neisseria gonorrhoeae. Staphylococcus epidermidis, Staphylococcus aureus, or Streptococcus agalactiae.

145. The method of claim 143, wherein the subject has a fungal infection, and the fungus is Candida albicans.

146. The method of claim 43, wherein the subject has a protist infection, and the protist is Trypanosoma cruzi, Plasmodium (such P.falciparum, P. vivax, . ovale, or . malariae), Trypanosoma briicei (such as T. brucei gambiense or T. brucei rhodesiense), or Leishmania.

147. The method of claim 143, wherein the subject has a viral infection, and the virus is hepatitis B, hepatitis C, or dengue vims.

148. The method of any one of claims 89 to 147, wherein the subject is a mammal.

149. The method of claim 148, wherein the subject is a human.

150. The method of claim 149, wherein the subject has a serum hepcid n concentration of less than about 100 ng/mL prior to administering the hepcidin or hepcidin analogue to the subject.

151. The method of claim 0, wherein the subject has a serum hepcidin concentration of less than 50 ng/mL prior to administering the hepcidin or hepcidin analogue to the subject.

152. The method of any one of claims 148 to 15 1, wherein the subject has a serum ferritin concentration greater than 100 ng/mL prior to administering the hepcidin or hepcidin analogue to the subject.

153. The method of any one of claims 48 to 5 1, wherein the subject has a serum ferritin concentration greater than 200 ng/mL prior to administering the hepcidin or hepcidin analogue to the subject.

154. The method of any one of claims 148 to 153, wherein the subject has a serum ferritin concentration greater than 300 ng/mL prior to administering the hepcidin or hepcidin analogue to the subject.

155. The method of any one of claims 148 to 154, wherein the subject has a serum ferritin concentration greater than 00 ng/mL prior to administering the hepcidm or hepcidin analogue to the subject.

156. The method of any one of claims 148 to 151, wherein the subject has a total body- iron content of about 40 to about 50 mg/kg prior to administering the hepcidin or hepcidin analogue to the subject

157. The method of any one of claims 148 to 151, wherein the subject has a total body iron content greater than 50 mg/kg prior to administering the hepcidin or hepcidin analogue to the subject. 58. The method of claim 157, wherein the subject has a total body iron content greater than 60 mg/kg prior to administering the hepcidin or hepcidin analogue to the subject.

159. The method of any one of claims 148 to 15 1, wherein the seram iron concentration of the subject is at least about 0 ,u.g/dL prior to administering the hepcidin or hepcidin analogue to the subject.

60. The method of claim 159, wherein the seram iron concentration of the subject is at least about 200 µ ά . prior to administering the hepcidin or hepcidin analogue to the subject.

161. The method of any one of claims 148 to 151, wherein the transferrin saturation of the subject is greater than about 50% prior to administering the hepcidin or hepcidin analogue to the subject.

62. The method of claim 161 , wherein the transferrin saturation of the subject is greater than about 90% prior to administering the hepcidin or hepcidin analogue to the subject.

163. The method of claim 148 or 149, wherein the subject has a serum hepcidin concentration of more than about 25 ng/mL following administration the hepcidin or hepcidin analogue to the subject.

164. The method of claim 148 or 149, wherein the subject has a seram hepcidin concentration of more than about 50 ng/mL following administration of the hepcidin or hepcidm analogue to the subject.

165. The method of claim 148 or 149, wherein the subject has a serum ferritin concentration less than 0 ng/mL following administration of the hepcidin or hepcidin analogue to the subject.

166. The method of claim 148 or 149, wherein the subject has a serum ferritin concentration less than 50 ng/mL following administration the hepcidin or hepcidin analogue to the subject.

167. The method of claim 166, wherein the subject has a total body iron content of less than 25 mg/kg following administration of the hepcidin or hepcidm analogue to the subject.

168. The method of claim 148 or 149, wherein the subject has a total body iron content less than mg/kg following administration the hepcidm or hepcidin analogue to the subject.

169. The method of claim 68, wherein the subject has a total body iron content less than 10 mg/kg following administration the hepcidin or hepcidin analogue to the subject. 170. The method of claim 48 or 149, wherem the serum iron concentration of the subject is less than about 200 ,ug/dL following administration the hepcidin or hepcidin analogue to the subject.

1 1. The method of claim 170, wherein the serum iron concentration of the subject is less than about 100 g/dL following administration the hepcidin or hepcidin analogue to the subject.

172. The method of claim 148 or 149, wherein the transferrin saturation of the subject is decreased to between % and 50% following administration the hepcidm or hepcidin analogue to the subject.

173. The method of claim 172, wherein the transferrin saturation of the subject is decreased to between 20% and 40% following administration the hepcidin or hepcidin analogue to the subject.

174. The method of any one of claims 89 to 173, wherem the hepcidin or hepcidin analogue has at least 60% sequence homology to SEQ ID NO 1.

175. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 1.

176. The method of any one of claims 89 to 173, wherem the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 1.

177. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has at least 60% sequence homology to SEQ ID NO 2

178. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 2.

179. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 2.

180. The method of any one of claims 89 to 73, wherein the hepcidin or hepcidin analogue has at least 60% sequence homology to SEQ ID NO 3.

181. The method of any one of claims 89 to 73, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 3.

182. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has 0% sequence homology to SEQ ID NO 3.

183. The method of any one of claims 89 to 173, wherem the hepcidin or hepcidin analogue has at least 60% sequence homology to SEQ ID NO 4. 84. The method of any one of claims 89 to 173, wherein the hepcidm or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 4 .

85. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has 00% sequence homology to SEQ ID NO 4.

6. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has at least 60% sequence homology to SEQ ID NO 5.

7. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue comprises at least 80% of SEQ ID NO 5 .

188. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 5.

9. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 6.

190. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 6.

191. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ D NO 7.

2. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 7 .

193. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 8 .

194. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 8.

195. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 9.

196. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has 00% sequence homology to SEQ ID NO 9.

197. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has at least 80% sequence homology to SEQ ID NO 10.

198. The method of any one of claims 89 to 173, wherein the hepcidin or hepcidin analogue has 100% sequence homology to SEQ ID NO 10.

A . CLASSIFICATION O F SUBJECT MATTER IPC (2017.01) A61K 38/17, A61P 3/00, C07K 14/575, A61K 38/22

According to International Patent Classification (IPC) or to both national classification and IPC B . FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC (2017.01) A61K 38/17, A61P 3/00, A61P 7/06, A61P 31/00, A61P 31/04, A61P 31/06, A61P 33/00, A61P 33/06, A61P 43/00, A61K 38/10, A61K 38/08, C07K 14/47, C07K 14/575, C07K 7/06, C07K 7/08, A61K 38/22

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See extra sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

X W O 2015/157283 A l MERGANSER BIOTECH LLC [US] 1-195 15 Oct 2015 (2015/10/15) Whole document. Especially figures 6 and 8.

X W O 2013/086143 A l THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US] 1-4,9-33,37-41,49, 13 Jun 2013 (2013/06/13) 50,53,54,60,61,64-101, Whole document. Especially pages 5, 46 and figures 5-9, 10B, IOC, 11A, 11B and 13B. 106-143,147-151, 159,160, 163,164,170, 171, 174-198

X Rivera, S. et al. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is 1,2,9,24,26,28,29, concentrated in ferroportin-containing organs. Blood (20050915), Vol. 106, No. 6, pp. 33,38,49,50,53,54,60, 2196-2199. Retrieved from: . 15 Sep 2005 (2005/09/15) Results and figures 1-3.

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents: later document published after the international filing date or priority "A" document defining the general state of the art which is not considered date and not in conflict with the application but cited to understand to be of particular relevance the principle or theory underlying the invention earlier application or patent but published on or after the "X" document of particular relevance; the claimed invention cannot be international filing date considered novel or cannot be considered to involve an inventive L document which may throw doubts on priority claim(s) or which is step when the document is taken alone cited to establish the publication date of another citation or other special reason (as specified) Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is "O" document referring to an oral disclosure, use, exhibition or other combined wi h one or more other such documents, such combination means being obvious to a person skilled in the art P" document published pri or to the international filing date but later "&" document member of die same patent family

Dale of the actual completion of the international search Date of mailing of the international search report

07 Dec 2017 14 Dec 2017

Name and mailing address of the ISA: Authorized officer Israel Patent Office SOMECH Erez Technology Park, Bldg.5, Malcha, Jerusalem, 9695101, Israel Facsimile No. 972-2-5651616 Telephone No. 972-2-5651762 Form P CT SA 2 0 (second sheet) (January 20 5) C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

X Continued (Rivera, S. et al.) 163,164,170, 171, 174-198

X WO 2010/065815 A2 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US] 89-101,106-143, 10 Jun 20 10 (2010/06/10) 147-15 1,159, 160,163,164, Whole document. Especially pages 7, 24, 25, 29-30 and figures 5-9. 170,171,174-198

X Portugal, S. et al. Host-mediated regulation of superinfection in malaria. Nature medicine (01 89, 106-108,133, 134, June 201 1), volume 17, number 6, pages: 732-737. Retrieved from: 0 1 Jun 20 11 (201 1/06/01) Supplementary information and figure 3(i).

Y 33,36,89,106-108, 133,134,143, 146,148, 174-198

X Preza, G. C. et al. Minihepcidins are rationally designed small peptides that mimic hepcidin 89,90, 106,107, 130, activity in mice and may be useful for the treatment of iron overload. The Journal of clinical 133,134,136-139,148, investigation (01 December 201 1), volume 121, issue 12, pages: 4880-4888. Retrieved from: 150,15 1,159, 160,163, . 164,170,171, 174-198 0 1 Dec 201 1 (201 1/12/01) Whole document. Especially figure 6, supplemental table 2 and page 4886.

X WO 2015/200916 A2 PROTAGONIST THERAPEUTICS 89-101,106-143, 30 Dec 2015 (2015/12/30) 147-15 1,159, 160,163,164, Whole document. Especially page 26, paragraphs [00444] and [00464] and figure 1. 170,171,174-198

Y Park, C. H . et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. Journal of 33-37, 143-147 biological chemistry (16 March 2001), volume 276, issue 11, pages: 7806-7810. Retrieved from: . 16 Mar 2001 (2001/03/16) Whole document.

P,X WO 2017/120419 A l LA JOLLA PHARMACEUTIAL COMPANY [US] 1-198 13 Jul 2017 (2017/07/13) Whole document.

P,X WO 2017/1 1741 1 A l PROTAGONIST THERAPEUTICS INC. 1-198 06 Jul 2017 (2017/07/06) Whole document.

P,X Jin, H . et al. Pharmacokinetics and pharmacodynamics model of synthetic human hepcidin 1-198 LJPC-401 following single dose administration in dogs. American Journal of Hematology (August 2017), Vol. 92, No. 8. Conference Abstract. 31 Aug 2017 (2017/08/3 1) Abstract.

For CT/ SA 2 10 (continuation of second sheet) (January 2015) Patent document cited search Publication date Patent family member(s) Publication Date report

WO 2015/157283 A l 15 Oct 2015 WO 2015157283 A l 15 Oct 2015

WO 2015157283 A9 03 Dec 2015

AU 2015243990 A l 10 Nov 2016

CA 2948283 A l 15 Oct 2015

CN 106456703 A 22 Feb 2017

EP 3129040 A l 15 Feb 2017

JP 20175 19810 A 20 Jul 2017

KR 20170002414 A 06 Jan 20 17

US 2015284429 A l 08 Oct 2015

US 93 15545 B2 19 Apr 2016

US 201705 1013 A l 23 Feb 2017

WO 2013/086143 A l 13 Jun 2013 WO 2013086143 A l 13 Jun 2013

AU 2009322260 A l 07 Jul 201 1

AU 2009322260 B2 12 Sep 2013

AU 2012327226 A l 27 Jun 2013

AU 2012327226 B2 14 Apr 2016

AU 2012327226 C9 16 Feb 2017

AU 2012327226 CI 02 Mar 2017

CA 2855 122 A l 13 Jun 2013

CN 102245626 A 16 Nov 201 1

CN 10401 1066 A 27 Aug 2014

EP 2373679 A2 12 Oct 201 1

EP 2373679 A4 30 May 2012

EP 2373679 B l 08 Mar 2017

EP 2788370 A l 15 Oct 2014

EP 2788370 A4 08 Jul 2015

EP 3208279 A l 23 Aug 2017

HK 1199892 A l 24 Jul 2015

232927 D O 31 Jul 2014

JP 2015504859 A 16 Feb 2015

Form PCT/ISA/210 (patent family annex) (January 2015) Patent document cited search Publication date Patent family member(s) Publication Date report

US 2012040894 A l 16 Feb 2012

US 8435941 B2 07 May 2013

US 20143361 10 A l 13 Nov 2014

US 9328140 B2 03 May 2016

US 2013203662 A l 08 Aug 2013

US 2016200765 A l 14 Jul 2016

WO 2010065815 A2 10 Jun 2010

WO 2010065815 A3 2 1 Oct 2010

WO 2010/065815 A2 10 Jun 2010 WO 2010065815 A2 10 Jun 2010

WO 2010065815 A3 2 1 Oct 2010

AU 2009322260 A l 07 Jul 201 1

AU 2009322260 B2 12 Sep 2013

AU 2012327226 A l 27 Jun 2013

AU 2012327226 B2 14 Apr 2016

AU 2012327226 C9 16 Feb 2017

AU 2012327226 CI 02 Mar 2017

CA 2855 122 A l 13 Jun 2013

CN 102245626 A 16 Nov 201 1

CN 10401 1066 A 27 Aug 2014

EP 2373679 A2 12 Oct 201 1

EP 2373679 A4 30 May 2012

EP 2373679 B l 08 Mar 2017

EP 2788370 A l 15 Oct 2014

EP 2788370 A4 08 Jul 2015

EP 3208279 A l 23 Aug 2017

HK 1199892 A l 24 Jul 2015

232927 D O 31 Jul 2014

JP 2015504859 A 16 Feb 2015

US 2012040894 A l 16 Feb 2012

US 8435941 B2 07 May 2013

Form PCT/ISA/210 (patent family annex) (January 2015) Patent document cited search Publication date Patent family member(s) Publication Date report

US 20143361 10 A l 13 Nov 2014

US 9328140 B2 03 May 2016

US 2013203662 A l 08 Aug 2013

US 2016200765 A l 14 Jul 2016

WO 2013086143 A l 13 Jun 2013

WO 2015/200916 A2 30 Dec 2015 WO 2015200916 A2 30 Dec 2015

AU 2015279571 A l 02 Feb 2017

CA 2953721 A l 30 Dec 2015

CN 107075574 A 18 Aug 2017

EP 3161 164 A2 03 May 2017

JP 2017523959 A 24 Aug 2017

KR 20170043509 A 2 1 Apr 2017

SG 11201610799W A 27 Jan 20 17

US 20173 13754 A l 02 Nov 2017

WO 2017/120419 A l 13 Jul 2017 WO 2017120419 A l 13 Jul 2017

US 2017246256 A l 31 Aug 2017

WO 2017/1 1741 1 A l 06 Jul 2017 WO 20171 1741 1 A l 06 Jul 2017

Form PCT/ISA/210 (patent family annex) (January 2015) B . FIELDS SEARCHED: * Electronic data base consulted during the international search ( ame of data base and, where practicable, search terms used) Databases consulted: Google Patents, CAPLUS, BIOSIS, EMBASE, MEDLINE, MARPAT, REGISTRY, Google Scholar, DWPI, Derwent Innovation Search terms used: *hepcidin*, mini-hepcidin*, minihepcidin*, hamp*, LEAP-1, LEAP*1, supplement*, serum or body iron (orferrum), rebound, recover*, overshoot*, ferritin, transferrin, TSAT, reduce, lower*, decreas*, absorpt*, absorb*, chelat*, erythropoiesis, hemochromatosis, sickle cell, hereditary hemochromatosis, anemia, malaria, *thalassemia, patient*.

Form PCT/ S 2 0 (extra sheet) (January 2015)